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Dissertation abstract  
 
Background  
Task-shifting of care and first-line treatment for people living with HIV (PLHIV) from doctors 
to nurses is feasible, effective and acceptable in sub-Saharan Africa. Since first-line 
resistance to antiretroviral therapy (ART) is increasing, comprehensive HIV care should be 
informed by viral load (VL) monitoring to ensure timely detection of treatment failure and 
switch to second-line ART if appropriate. Patients identified with a first elevated VL (FEVL) 
enter a cycle with extra counselling sessions, VL re-testing, and potential regimen switch, 
putting additional strain on scarce human resources. However, identification of treatment 
failure and its management remains largely doctor-led and there are limited results from 
programmes with nurse-led management of treatment failure.   
Health service-delivery in the Democratic Republic of Congo (DRC) is challenging in a weak 
health system, pressured by epidemics and political unrest. Despite low HIV prevalence in 
the capital Kinshasa (1.6%), many PLHIV present with advanced disease and early mortality 
is high. HIV care and treatment, VL testing and second-line switch in decentralised facilities 
in Kinshasa is exclusively managed by nurses, but results have so far not been documented.  
Methods  
Patient outcome data in three primary care facilities in Kinshasa, were routinely collected 
since ART introduction in 2002 and entered in the national Tier.net database. A protocol 
(Section A: Study protocol) was developed with detailed methods and procedures for a 
retrospective analysis of patient outcomes after having had a FEVL (≥1000 copies/ml).  The 
protocol includes analysis of predictors for favourable outcomes (i.e. retained and with VL 
re-suppressed at 12 months after first high VL or administratively censored or transferred 
with suppressed VL), and analysis of compliance to existing protocols. The protocol received 
approval by ethics boards of the Ministry of Health of the DRC and the University of Cape 
Town.  
A structured literature review was conducted (Section B: Literature review), critically 
appraising peer-reviewed publications describing outcomes of PLHIV on ART after first-line 
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failure in sub-Saharan Africa under programmatic conditions. The review included studies 
where treatment failure and switch were managed by medical doctors, due to paucity of 
data of nurse-led management of treatment failure. Predictors for outcomes after failure 
and switch to second-line were also extracted from available literature.  
A journal-ready manuscript (Section C: Manuscript) presents the findings of the analysis 
conducted on patients with a FEVL in three decentralised nurse-led facilities in Kinshasa, and 
predictors for favourable outcomes.  
Results  
Of 294 adults with FEVL who did not switch to second-line before confirmatory VL, 82% had 
a second VL (VL2) done within 24 months of FEVL at a median (interquartile range [IQR]) of 
4.0 (3.1-5.6) months) after FEVL. Among patients with VL2 done, 69% had VL2 
≥1000copies/ml, of whom 75% switched to second-line a median of 1.1 (IQR, 0.7-2.0) 
months after VL2. Among the 85% of patients who were not deceased, LTFU or transferred 
out by 6 months after second-line switch, 82% had VL<1000 copies/ml. Results were similar 
for children. After routine VL implementation, losses in the VL-cascade steps were slightly 
higher, but timelines for VL2 and switch and correct switch were mostly respected. 
Undergoing VL2 >6 versus ≤3 months after FEVL and switching 1-3 versus ≤1 month after 
VL2 ≥ 1000copies/ml were independently associated with lower odds of a favourable 
outcome.  
Conclusion  
Exclusively nurse-managed detection of virologic failure and switch to second-line ART in 
decentralised health facilities yielded acceptable outcomes in our cohort in urban Kinshasa. 
Early detection and fast switch can help improve retention and viral suppression following 
virologic failure. Task-shifting along the viral load cascade is a feasible and safe strategy in 
settings with limited human resources and growing viral resistance. 
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Background and justification  
Significant progress has been made by many countries to reach the 90-90-90 targets of the 
Joint United Nations Programme on HIV and AIDS (UNAIDS) (1). The latest estimates of the 
global so-called ‘care cascade’, show that 70% of people living with HIV/AIDS (PLWHA) know 
their status, 77% of them are on antiretroviral treatment (ART) (53% of all PLWHA) and 82% 
of those on ART (44% of all PLWHA) are virally suppressed (2). Uptake of the 2015 
recommendations of the World Health Organisation (WHO) to treat all HIV-positive patients 
has contributed to the progress, including in sub-Saharan Africa (3). Task-shifting of ART 
initiation and follow-up to nurses is a strategy that has proven to work for those patients 
deemed ‘stable’, i.e. with a suppressed viral load. Not only does it improve access by 
decentralising care and decongesting facilities, task-shifting has also resulted in non-inferior 
patient outcomes when compared to doctor-led care of ART patients (4). Nurse managed- 
care is cost-effective for ART patients and acceptable to patients and doctors (4,5).  
Many patients, however, follow a dynamic, non-linear path through this ‘cascade of care’ 
and many get lost at every step. In Sub-Sahara Africa, were the burden of HIV is high and 
many health systems weak, these losses are particularly important, with patients cycling in 
and out of the different steps throughout their lifetimes (6). Also, while the global focus has 
been on its first three steps, the ‘cascade’ fails to account for patients who do not suppress 
their viral load (VL) (7). In 2013, these were estimated to represent 15% of HIV patients in 
low-and middle income countries (LMIC) (8). First-line resistance is on the rise in sub-
Saharan Africa, and care informed by VL monitoring improves early detection of high VL and 
appropriate switch to second-line ART (9–11).  
Patients identified with a first high VL, who often already face barriers to treatment 
adherence, enter an even more complex cycle. Additional steps include enhanced 
adherence counselling (EAC), VL re-testing 3 to 6 months later and switch to second-line 
treatment depending on the results. Those who re-supress on second-line treatment can re-
enter the original cascade (3). Again, patients drop out at every step. Not surprisingly, the 
complex care for these patients adds an additional burden to the already overstretched 
health systems with limited medical staff.  Still, task-shifting of identification of treatment 
failure and its management, including initiation of second-line ART, has hardly been 
documented. A recent study from Lesotho is the first to have described outcomes from a 
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nurse-led second line cascade, called the ‘failure cascade’ (7). In this high burden country, 
nurse-driven decentralised HIV care is the backbone of the HIV programme (12). While 
patient follow-up was completely nurse-led, the decision to switch and the choice of the 
second-line regimen were made with support of a medical doctor and needed approval of a 
national central committee.1 
The study showed poor results; out of all patients in the Lesotho cohort who had an initial 
high viral load, only 41% had a suppressed VL at 18 months. Re-suppression after EAC, and 
timely switch to second-line for those eligible, were associated with better outcomes (7). 
The poor outcomes are not necessarily nurse-related, as delays in second-line switch by 
general practitioners were also reported in a large study in South Africa (13). Review data 
from LMIC showed high rates of virologic failure on second-line treatment even if doctors 
led care; cumulative proportions were 23% at one year and 38% at three 3 years, but low 
mortality (14). A multi-centre randomised trial in three West-African cities, reported that 
31% of patients did not re-suppress after 1 year on the WHO recommended second-line 
regimen. VL above 100,000 copies/ml at baseline was associated with more virologic failure 
(15). In South Africa, Rohr et al. described that only 37% of patients identified with virologic 
failure switched to second line, and 14% of those experienced virologic failure. In patients 
with low peak CD4 on first line, delays of switch were associated with higher mortality and 
more second-line failure (16,17).  
In the Democratic Republic of Congo (DRC), despite a low HIV prevalence of 1.2%, nearly 
22,000 people died of HIV in 2015 (2). Less than 20% of facilities in the capital city of 
Kinshasa offer HIV treatment services, and those that do are overcrowded, suffer from 
medicines stockouts, lack of diagnostic tests and insufficient medical staff (18,19). In the 
DRC, only 42% of PLWHA are on treatment and 31% of all PLWHA are estimated to suppress 
their VL (2). HIV care is largely nurse-managed, including ART initiation and second line 
switch in primary care facilities. In Kinshasa, to further decongest facilities and reduce 
stigma, patients with supressed VL are referred to patient-managed ART pick-up points in 
the community with excellent retention in care (20). In 2016, the Ministry of Health adopted 
a plan to fast-track the HIV response and reach 90-90-90 by 2020, including through 
immediate treatment for all PLWHA, further decentralisation and task-shifting and improved 
 
1 Personal correspondence with the author  
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access to VL testing (21). This will lead to detection of larger numbers of patients being 
identified with virologic failure, needing decentralised care. So far, exclusive nurse-led 
second-line initiation and management has not been described.  
Increasing cases found with virologic failure, on top of test and treat all policies, increase the 
need for decentralisation and task shifting, including of second-line care. Research is needed 
to explore possible benefits and disadvantages of nurse-led management of patients who 
do not suppress their VL. This study will describe patient outcomes after nurse-led 
identification and management of treatment failure in urban primary care clinics in 
Kinshasa.  
 
Aim  
The aim of the study is to describe the outcomes throughout the cascade of care of ART 
patients identified with virologic failure and whose care was led by nurses in public sector 
MSF supported health care facilities in Kinshasa, DRC, as well as compliance with treatment 
protocols and outcome predictors.  
 
Objectives  
 
Primary Objective  
The primary objective of this study is to describe for patients identified with virologic failure, 
i.e. at least one viral load 1000 copies/ml, between January 2007 and December 2017 and 
on ART for a minimum of 6 months, proportions at each step of the “failure cascade”, i.e. 
from virologic failure on, as well as treatment outcomes (viral load, retained in care, 
transferred out, lost-to-follow up (LTFU) and death) at 6, 12, and 24 months (if appropriate) 
since virologic failure in public sector health care facilities supported by Médecins Sans 
Frontières (MSF) in Kinshasa.  
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Secondary Objectives  
The secondary objectives are;   
i. To describe existing protocols and the implementation of decentralization of care to 
primary care clinics, nurse led HIV care, and viral load monitoring between 2007 and 2017 
in these facilities.  
ii. To describe compliance to protocols existing (first viral load (VL1) done, timing of first viral 
load, second viral load done, timing of second viral load (VL2), timing between detecting 
virologic failure criteria and second line switch, and correct regimen change) for all 
patients receiving care in these facilities between 2015 and 2017.  
iii. To analyse predictors of favourable treatment outcomes in those patients with at least 
one viral load of 1000 copies/ml.  
 
Methods  
 
Study Design 
This is a retrospective cohort analysis, through examination of routinely collected clinical 
information from patients who have received care at three public health care facilities 
supported by MSF in the city of Kinshasa.  
 
Study Setting  
The study data will be collected from three urban primary care facilities supported by MSF 
in the capital city of the DRC, Kinshasa. All HIV-care in these facilities is exclusively provided 
by nurses. The HIV prevalence of 1.6% in the capital is higher than the national average 
(1.2%) (21).  
MSF has been providing HIV services in Kinshasa since 1996 and ART since 2002. Initiation 
and follow-up of ART patients has been decentralised to nurse-led primary care facilities 
since 2008 and follow-up to community pick-up points since 2010 (20). Routine VL 
monitoring was implemented in 2015 in MSF supported primary care facilities.  
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Before 2015, identification of treatment failure was based on clinical and/or immunological 
criteria confirmed with targeted viral load testing. Routine monitoring was done exclusively 
with CD4-count and clinical assessment. A viral load platform, installed at the MSF referral 
hospital, has been functional since mid-2015. The initial routine viral load protocol prescribed 
that all newly initiated patients on ART receive a VL test at six months in care (or when coming 
for a routine clinical visit if on ART for longer), and yearly afterwards. Patients with a first VL 
1000 copies/ml (VL1) should receive EAC. EAC consists of two meetings with a counsellor; 
one at return of VL1 results, and one a month later at ART pick-up. In the first session, 
particular attention is given to exploration of the patients’ barriers to adherence and potential 
solutions, while in the second session the solutions are evaluated and emotional barriers are 
further explored. The patients then get re-tested (VL2) three months after VL1. If the second 
VL is not below 1000 copies/ml, patients are switched to second line ART as soon as possible. 
Patients with a viral load of <1000 copies/ml were referred to a facility fast-track circuit or a 
community pick-up point for medicines pick-up between VL tests. Since January 2017 the 
protocol was adapted to a first VL at three months on ART. Phone-based follow-up was 
implemented for all routine or follow-up VL tests.  
 
Study Population and Period  
For the primary objective, the study population includes all ART patients enrolled at one of 
three decentralised MSF-supported and nurse-managed primary care facilities, who had been 
on ART for a minimum of six months by December 2017 and had been identified as having 
immunological or clinical failure or with at least one VL of 1000 copies/ml in the city of 
Kinshasa between January 2007 until December 2017. Follow-up data will be collected until 
the end of 2017. From the same population, those for whom outcome data are available (i.e. 
excluding no VL result or transferred out) will be subject to analyse predictors for a favourable 
outcome (secondary objective (iii)).  
For secondary objective (ii), the entire ART cohort enrolled in the three facilities between 
January 2015 until December 2017 will be included, regardless of VL failure status, in order to 
assess the compliance with a first viral load done for all patients. In October 2017, the 
complete cohort was around 1400 patients. 
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Data variables and definitions  
Primary objective: To describe for patients identified with virologic failure, i.e. at least one 
viral load 1000 copies/ml, between January 2007 and December 2017 and on ART for a 
minimum of 6 months, proportions at each step of the “failure cascade”, i.e. from virologic 
failure on, as well as treatment outcomes (viral load, retained in care, transferred out, lost-to-
follow up (LTFU) and death) at 6, 12, and 24 months (if appropriate) since virologic failure in 
public sector MSF supported health care facilities in Kinshasa. 
Patient outcome variables will be collected at 6, 12 and 24 months after initial high VL, 
where possible. Patients will be classified into one of the following categories after VL1 
1000 copies/ml;  
• VL not done or no results  
• Switched to second line  
• VL2 done and results available, further divided into;  
o VL 2 1000 copies/ml, further divided into;  
▪ Switched to second line  
▪ Not switched  
o VL 2 <1000 copies/ml, further divided into;  
▪ Referred to fast-track 
▪ Referred to PODI 
▪ Remained in normal care 
In each of those categories the patient outcomes will be measured and classified as one of 
the following:  
• Retained in care with supressed viral load (<1000 copies/ml)  
• Retained in care with unsuppressed viral load (1000 copies/ml)  
• Retained in care with viral load status unknown  
• Death, as confirmed by a family or community member after phone follow-up  
• Transferred out, to a clinic outside the MSF supported clinics, as confirmed by the 
patient in writing  
• Lost-to-follow-up (LTFU), when a patient did not return for a follow-up visit 90 days 
after the scheduled visit and the reason could not be confirmed 
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To know the patient’s position in the cascade the following variables will be collected:  
• Date of ART initiation  
• If patient had a VL1, date of VL1  
• If the patient had a VL2, date of VL2 
• If the patient was switched to second-line ART, date of switch to second-line ART  
• For patients with re-supressed VL, whether they were referred to a community 
distribution point (PODI), a fast track system or remained in regular care 
A dummy figure to present the patient flow for the outcomes is added in Appendix 1. The 
outcomes for patients with at least one VL >1000 copies/ml (primary objective) are shown in 
blue.  
Secondary objective (i): To describe existing protocols and the implementation of 
decentralization of care to primary care clinics, nurse led HIV care, and viral load monitoring 
between 2007 and 2017 in these facilities.  
Descriptive information will be used for the narrative of implementation.  
Secondary objective (ii): To describe compliance to protocols existing (first viral load (VL1) 
done, timing of first viral load, timing of second viral load (VL2), timing between detecting 
virologic failure criteria and second line switch, correct regimen change) for all patients 
receiving care in these facilities between 2015 and 2017.  
 
All patients on ART between 2015 and 2017 will be considered and will be classified into one 
of the following categories;  
• On ART < 6 months in December 2017 
• On ART  6 months in December 2017, further divided into;  
o VL not done or no results  
o VL1 done and results available, further divided into; 
▪ VL1 < 1000 copies/ml  
▪ VL1  1000 copies/ml; 
Like for the primary objective, patients will be classified into one of the following categories 
after VL1 1000 copies/ml;  
• VL2 not done or no results  
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• Switched to second line  
• VL2 done and results available, further divided into;  
o VL 2 1000 copies/ml, further divided into;  
▪ Switched to second line  
▪ Not switched  
o VL 2 <1000 copies/ml, further divided into;  
▪ Referred to fast-track 
▪ Referred to PODI 
▪ Remained in normal care 
In addition to the data collected for the primary objective, the time to the next step in the 
cascade and completion rates will be calculated and compared to existing protocols at that 
time to analyse compliance.  
The dummy figure 2 in appendix 2 shows the patient flow for the secondary objective (ii).  
Secondary objective (iii): To analyse predictors of favourable treatment outcomes in those 
patients with at least one a VL >1000 copies/ml.  
Additional variables to be collected (where appropriate) include:  
• Patient age at initiation on ART  
• Patient age at VL1  
• Patient gender  
• Results of VL1  
• Results of VL2  
• Facility where enrolled  
• First-line ART treatment regimen  
• Second-line ART treatment regimen  
• Previous ART exposure 
• Time on ART at VL1 
• CD4 at ART initiation and at VL1 
• Delay between diagnosis of virologic failure and initiation of second line ART 
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A favourable outcome will be defined as retained and suppressed, including those ‘retained 
in care with suppressed viral load’ in one of the MSF supported facilities. All other outcomes 
are classified as ‘not retained or suppressed’ and include the other outcome possibilities. 
The analysis will be restricted to those for whom a result is available. The cut-off for 
availability of VL2 will be put at 12 months.  
Indicators that will be explored as possible predictors for a favourable outcome, when 
possible;   
• Patients age at ART initiation and at VL1, gender, ART regimen, facility, VL result known  
• VL1 result, VL2 done or not, VL2 result  
• Time from VL1  1000 copies/ml to VL2 
• Time between diagnosis of treatment failure (VL21000 copies/ml) and initiation of 
second line ART 
• Previous ART exposure  
• CD4 at ART initiation  
• Time on ART at VL1, CD4 at VL1  
 
 
Research procedures and data collection methods  
All quantitative data used in this study will already have been collected as part of routine 
clinical patient follow-up and reporting. Routine clinical data and patient characteristics will 
have been entered by nurses into each patient’s medical record. Viral load measurements will 
have been done by Abbott Real-Time Viral Load at the MSF referral hospital, after sample 
collection in the facility, transported as a dried blood spot. Viral load results will have arrived 
at the facility as a paper document and are kept in an excel based database. Data clerks daily 
enter all patient data from the different paper-based clinical record into the MSF project 
database, the national standard Tier.Net (Tier.Net v1.2.2., 2011). Once the record is entered 
into MSF project databases, it is de-identified and the patient is assigned an anonymous 
patient number. Data cleaning on-site will be done to check for inconsistencies in data entry 
and responses. De-identified patient information will be extracted from the Tier.net database 
into a specific study excel database. 
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Descriptive information on the history and chronology of implementation of the different 
programme aspects will be gathered from review of existing literature, including grey 
literature, MSF programme documents, and guidelines and documents from the Ministry of 
Health (MoH). Interviews with key MSF and MoH staff will be conducted to complete the 
information.  
 
Statistical analysis 
All analyses will be performed using Stata/IC 14.1 (StataCorp, Stata Statistical Software: 
College Station, TX). Participants’ baseline characteristics and treatment outcomes at 
different points in time will be assessed using means with their standard deviations (SD), or 
medians with corresponding interquartile ranges (IQR) for continuous variables, and 
frequencies and proportions for categorical data. Comparisons of means and medians will 
be calculated using t-test or the ANOVA and nonparametric k-sample tests respectively. 
Differences in proportions between groups will be reported using chi-squared tests or 
Fisher’s exact as appropriate. Multivariate logistic regression will be used for analysis of 
fixed outcomes predictors. Cox-regression will be used to analyse time bound outcome 
predictors. A two-sided alpha <0.05 threshold will be considered as statistically significant 
for all analyses.  
 
Ethical considerations  
 
Ethical approval  
The data are routinely collected for programme monitoring and evaluation of the national 
HIV programme in the DRC and patients enrolling for routine care are not asked for 
informed consent. Beyond submission to the Institutional Review Board (IRB) of the Ministry 
of Health in the DRC, full ethics exemption for routinely collected data will be sought from 
the MSF Ethical Review Board. The protocol will also be submitted for expedited review to 
the IRB of the University of Cape Town. The principal investigator is responsible for the 
overall ethical compliance of the study. The study will be conducted in accordance with the 
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Council for International Organisations of Medical Sciences (CIOMS) International Ethical 
Guidelines for Health-related Research Involving Human Subjects (22) and International 
Ethical Guidelines for Epidemiological Studies (23). We commit to sharing study results with 
participants of the study or clinicians who treat them.  
 
Risks and benefits  
This retrospective analysis does not cause any physical harm to participants, who did not 
receive differential treatment as compared to other patients in the DRC, resulting from this 
study. Nevertheless, use of medical data beyond the immediate clinical care exposes the 
patient to possible breaches of confidentiality, including the patients’ HIV status. Evaluation 
of nurse adherence to protocols entails a possible risk of negative feedback for those nurses 
who do not adhere optimally. We plan to mitigate these risks by anonymizing data and 
allowing only investigators access to data and databases. Facility names will also be coded 
so that individual facilities cannot be identified in any research outputs.  
There are potential benefits for the study participants and for care and treatment for ART 
patients in general. A better understanding of risk factors for adverse outcomes in second 
line patients and protocol implementation may lead to better care and patients’ outcomes 
in the included facilities, the DRC and beyond. As there is currently a gap in the literature on 
nurse-managed care for second-line patients, the results of this study are of key importance 
for policy and practice nationally and internationally.  
 
Privacy and confidentiality  
Investigators who will do the analysis will receive the secondary data anonymised and 
coded. Participants’ names will thus not be used in this study and only aggregate data will 
be presented. Facility names will not be made public but will be coded. Confidentiality will 
be maintained by keeping data collection forms locked in a secure cabinet, while the 
electronic data file will be kept in a password and firewall protected computer. Forms, lists, 
logbooks and any other lists that link participant codes to other identifying information will 
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be stored in a separate, locked file in an area with limited access. Data sets will be 
maintained securely for five years after completion of the study. 
 
Collaborative partnerships 
The study will involve collaborating partners from the National HIV programme at the 
Congolese Ministry of Health. Representatives of the collaborative institutions will be 
represented on the study manuscript and any publication.  
 
Dissemination  
The results of this study will be presented in local and national stakeholder meetings and 
will be made available to patients and health care workers of the participating facilities. The 
manuscript will be submitted for publication in a peer-reviewed journal and the findings 
might be presented at national and international conferences.  
 
Timetable  
Table 1 presents the planned timeline for the consequent steps in the finalisation of the mini-
dissertation and manuscript.  
Table 1: Timetable for finalisation of mini-dissertation and manuscript  
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Budget 
The study will be done using secondary analysis of routinely collected data and no additional 
costs are anticipated during the study. The student researcher will perform the data 
manipulation, analysis and write-up free of charge.   
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Post manuscript  
 
A number of changes were made to the study that deviate from the original protocol, none 
of which had ethical implication for patients.  
Secondary objective (i)  
We did not include secondary objective (i) in the final manuscript as an outcome but added 
it as part of the setting in the methods section.  
Timelines  
Due to unanticipated operational delays, and delays in obtaining approval from the relevant 
ethics bodies, the time schedule was delayed with six months.  
Enhanced adherence counselling  
We did not analyse proportions of patients who went through EAC, as these data were not 
available in the Tier.net database.  
Fast-track, PODI 
We did not report on referrals to fast-track re-fills or PODIs, as these data were not available 
in the Tier.net database. 
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Introduction 
Sub-Saharan Africa carries the highest burden of HIV in the world, and the largest gap in 
qualified health personnel (1).  Cohorts of people living with HIV (PLHIV) requiring lifelong 
follow-up are growing, due to better diagnostics and provision of antiretroviral treatment 
(ART) regardless of immunological status. Global focus has been on increasing the number 
of patients who are stable in the “cascade of care” (i.e. 90% of PLHIV know their status, 90% 
of these are on treatment, and 90% of those suppress the virus) (2). However, rising 
resistance to first-line ART has led to growing numbers of patients who enter the “viral load 
(VL) cascade”, i.e. VL testing, adherence sessions, re-testing and regimen changes, 
particularly in sub-Saharan Africa (3–5). While the World Health Organization (WHO) 
recommends task shifting of first-line HIV care to nurses, management of the VL-cascade 
and the decision to switch is still reserved for medical doctors in most African countries (1) .  
30% of the worlds AIDS-related deaths and 21% of all new HIV-infections, occur in West- 
and Central Africa, where treatment coverage was 39% and viral suppression 29% among all 
PLHIV in 2017  (2,6). All countries in the region are considered low HIV-prevalence (<5%), 
and HIV competes with other health conditions in terms of financial support, infrastructure 
and human resources (7). In the Democratic Republic of Congo (DRC), a challenging country 
to provide health services, VL testing and second-line switch is fully nurse-led in 
decentralised facilities (8,9). The ministry of health is scaling up routine VL testing and 
treatment for all PLHIV since 2016 (10).  
Benefits of task-shifting and decentralisation of first-line care have been reported, as well as 
patient outcomes when follow-up after treatment failure is doctor-led (11–13). We propose 
a study evaluating outcomes from patients after a first elevated VL (FEVL) in an exclusively 
nurse-managed and decentralised cohort in the DRC (Section A). A literature review is 
conducted focusing on African studies describing patient outcomes after first-line failure, in 
observational cohorts, either nurse-or doctor-led.  
Objectives  
This literature review aims to examine existing literature presenting outcomes, and their 
determinants, of PLHIV along the VL-cascade in routine settings, in order to put the 
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proposed study (Section A) into a context of current academic evidence. We focus on 
mortality, retention in care and virologic outcomes.  
The objectives of the review are, for African cohorts,   
• To identify all published literature with focus on treatment outcomes of PLHIV along 
the cascade after first-line failure and predictors for those outcomes 
• To appraise the identified evidence in terms of availability, quality and comparability, 
allowing for critical interpretation of the results,  
• To summarize the results, interpret the findings and identify areas where additional 
research is needed.  
 
Search strategy  
A search was conducted using the PubMed interface (United Status National Library of 
Medicine, National Institutes of Health) of the Medline digital archive using a combination 
Medical Subject Headings (MeSH) and keywords. No language restriction was applied. The 
search included published articles until June 30, 2018. The following search terms were 
used:  
Table 1: Search terms for literature review  
 ((HIV [MeSH] OR HIV Infections [MeSH] OR HIV OR human immune deficiency syndrome OR acquired immune deficiency syndrome 
OR immunodeficiency syndrome OR HIV/AIDS OR AIDS) 
 OR  
 (Antiretroviral Therapy, Highly Active [MeSH] OR Anti-HIV Agents [MeSH] OR antiretroviral OR anti-retroviral OR antiviral OR anti-HIV 
OR anti-HIV OR HAART OR ARV OR ART)) 
AND  (("second-line outcomes " OR "outcomes after high viral load" OR "second-line treatment outcomes") 
 OR  
 (Treatment Failure [MeSH] OR Second-line therapy [MeSH] OR second-line therapy OR therapy switch OR treatment failure OR 
virologic failure OR high viral load OR drug resistance) 
 OR  
 (cascade of failure OR failure cascade OR second-line cascade OR viral load cascade)) 
AND  (Africa OR African OR Algeria OR Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR Cameroon OR Canary Islands OR 
Cape Verde OR Central African Republic OR Chad OR Comoros OR Congo OR Democratic Republic of Congo OR DRC OR Djibouti OR 
Egypt OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea OR Ivory Coast OR “Cote d'Ivoire” OR Jamahiriya OR Kenya 
OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mayotte OR Morocco OR 
Mozambique OR Namibia OR Niger OR Nigeria OR Principe OR Reunion OR Rwanda OR “Sao Tome'' OR Senegal OR Seychelles OR 
''Sierra Leone'' OR Somalia OR St Helena OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR ''Western Sahara'' 
OR Zaire OR Zambia OR Zimbabwe) 
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Inclusion and exclusion criteria 
Inclusion criteria: 
• Observational cohort studies in Africa reporting patient outcomes after virologic 
(VF), immunological (IF) or clinical failure (CF) on first-line treatment 
• Earliest start of follow-up was any time from ART start to second-line switch 
• ≥1 patient followed after switch to second-line  
Exclusion criteria:  
• Observation start at/after treatment failure on second-line  
• If follow-up started at switch, studies only reporting comparative outcomes between 
different regimens and not overall outcomes, studies limited to children, and 
publications limited to TB/HIV co-infected patients were excluded.  
 
Figure 1: Flow diagram for selection of articles for literature review 
ART = antiretroviral treatment 
 
492 articles yielded though the search were scanned by examination of the abstracts; 32 of 
these met the inclusion criteria (Figure 1). Two additional articles were included based on 
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the references from articles found with the search criteria. Two articles were excluded due 
to overlap with another included article (14,15). Two articles which included patients from a 
second paper by the same author, focusing on genotyping, are discussed but not tabulated 
(16,17). 30 articles were thus retained. 
 
Characteristics of included studies 
Focus in the cascade and general aim  
Five included studies follow cohorts through the entire cascade from ART initiation until 
clinical or virologic outcomes after switch to second-line (Table 1.A). Three of these focused 
on long-term outcomes (4-10 years) for all patients, including those switched (18–20). The 
two others were comparative cohort studies, focusing on the impact of switch to second-
line on mortality (21,22). Ten articles enrolled patients at FEVL (3,23–26), confirmed 
virologic failure (VF) (27–29), or immunological failure (IF) (30,31) until ≥1 patient had 
outcomes after second-line switch (Table 1.B). These articles will be most comparable in 
scope to the results of our protocol, in particular two covering the full VL-cascade (3,32). 
The studies mainly focused on the impact of switch (30,31), or delays in switch on clinical 
outcomes (25,26,29), and one on predictors for switch (27). The remaining 15 articles 
included cohorts of patients on second-line and report outcomes (Table 1.C).   
Role of nurses  
11 articles specified in their methods which cadre was responsible for the management of 
patients. Two articles from the same cohort in Lesotho, specified that care was nurse-led, 
but switch to second-line required approval by a second-line committee (3,23)2. Four 
articles specified nurse-led programmes (18,33), or including nurse-led clinics (27,34) with 
management of virologic failure and switch to second-line by doctors. A multi-centered 
study wrote that nurses, clinical officers or physicians provided care (35). Other authors 
specified care was provided by medical doctors (21,36), clinicians (29), or that a clinical team 
was responsible for switch (37). Other studies did not report on the staff cadre managing 
patients.  
 
2 clarified through personal correspondence with the author Labhardt, November 2017.  
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Study setting, population and period  
All studies were from sub-Saharan Africa. Five studies including >1 country (range 2-13), one 
of which included Asian countries (35), presented only overall and not individual country 
outcomes (22,26,31,38). 13 studies were from South Africa, four more included South Africa 
among other countries (22,26,35,38) . Six other studies included cohorts in other Southern 
African countries with an high HIV-prevalence (>10%) (6); in Uganda (29,39), Lesotho (3,23), 
Malawi (28) and Malawi and Zambia (31). Three cohort studies were conducted in the West-
and Central African region3 (in Senegal (20) and Nigeria (37,40)), and three others included 
countries from that region among other countries (22,35,38). The remaining studies were 
from East-Africa (21,30,33,41). Routine conditions in urban Congo probably compare best to 
other countries in West-and Central Africa for delivery of HIV services. 10 studies were from 
urban, five peri-urban, and four from rural settings. The Senegalese and Nigerian cohorts,  
followed by East-African contexts, present a closer contextual comparison to DRC compared 
to Southern African countries with more advanced HIV-programmes (2). Patients were 
recruited between 1998 and 2015. Over time, access to VL monitoring and second-line 
regimens has increased, with many countries shifting from targeted to routine VL 
monitoring.  Earlier studies had more opportunity for longer follow-up. The most recent 
studies and those covering cohorts in a similar period (2007-2017) are preferred for 
comparison with our results.  
Study design and follow-up   
18 studies used retrospectively collected data, all others gathered data prospectively. 
Prospectively collected studies have a quality advantage, because researchers can a priori 
decide on data to be collected and how to limit the above biases. Follow-up from ART 
initiation ranged from two to 10 years (Table 4), with follow-up from treatment failure 
between 24 weeks and around two years. Cohorts starting observation from second-line 
had 6-36 months follow-up.  
 
 
 
3 I used the United Nations denomination of West-and Central Africa for the region containing 25 countries which have 
with low HIV-prevalence (<5%), low HIV-coverage (39%), and competing health priorities in common (6). 
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Criteria for switch to second-line  
Criteria for switch to second-line ART are site-and time-dependent, varying e.g. with 
adoption of WHO guidelines and availability of diagnostic tools. Two studies relied only on IF  
as switch criteria (30,31). Three studies with different sites used site-specific criteria 
(22,35,38), four reported that any reason for switch (VF, IF, CF or first-line toxicity) was 
included (33,37,40,41). Two studies allowed either IF or VF as switch-criteria (20,21), and all 
other studies based switch on VF; targeted (28,39), one elevated VL (19,42) and toxicity (36) 
or two elevated VL results, with different thresholds (80-5000 copies/ml) (3,18,23). One 
study required genotyping results to confirm resistance (24).   
 
Results and discussion  
The results are divided up in four parts; characteristics of included patients (Table 3), 
descriptive proportions of outcomes along the cascade (Table 4), outcomes at different 
time-points (Table 5), and outcome predictors (Table 6). Table 5.A and 6.A report outcomes 
after treatment failure, table 5.B and 6.B report outcomes measured after second-line 
switch, with some articles included twice.  
Patient characteristics  
Characteristics presented are only those patients with high VL or confirmed VF (Table 2.A), 
and those on second-line (Table 2.B). 
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Table 2: Characteristics of included studies  
A. Studies including all ART patients and those who fail first-line ART  
B. Studies restricted to patients who fail first-line ART  
C. Studies restricted to patients who switch to second-line ART 
  Table 2.A         
 aCôte d’Ivoire, Kenya, Malawi, Rwanda, Senegal, South Africa, Uganda, Zimbabwe 
 
Reference Study setting and period Design Sample size Inclusion and exclusion criteria (excl.) Criteria for switch to second-line 
Barth et al. 2011 (19) Rural South Africa,  
clinic  
 
Retrospective 
cohort 
735 on ART  
117 (20% of 583 who > 3 mo FU) failure  
 
-initiated on ART  -1 VL≥ 1000 copies/ml > 3 months after initiation 
Boulle et al. 2010 (18) Peri-urban South Africa, 
clinics, 2001 - 2007  
Prospective 
cohort  
7,323 on ART  
152 (14% of RIC at 5 years) failure  
-ART-naive at initiation -2 VL≥ 5000 copies/ml  
De Beaudrap et al. 
2013 (20) 
Senegal, 
1998 - 2010  
Prospective 
cohort  
366 on ART  
79 (24% of those with initial virologic 
success) failure  
 
-initiated on 2 NRTI +PI/NNRTI 
- ≥ 6 mo FU 
- ≥1 VL done after baseline VL  
 
after initial VL <500 copies/ml:  
-2 consecutive VL ≥1000 copies/ml or 
-1 VL ≥1000 copies/ml & CD4 & 50% drop in CD4-peak 
value/ return to ≤ pre-ART CD4 or 1 VL ≥5000 copies/ml 
Hawkins et al. 2017 
(21) 
Urban Tanzania, clinics,  
initiated 2004-2012 
Prospective 
cohort  
47,296 on ART 
9,248 (10%) failure  
-  15years  
- on first-line ART 24 wk after initiation 
-1 VL > 10,000 copies/ml ≥ 24 wk on ART and/or  
-50% drop in CD4-peak value / return to ≤ pre-ART CD4 
Keiser et al. 2011 (22) 11 urban programmes  
in 8 countriesa  
initiated 2002 - 2006 
Retrospective 
cohort  
16,591 on ART 
705 (4%) failure 
 
-  16 years  
- ART-naive at initiation 
- initiation with NNRTI  
- ≥ 6 mo FU 
Site-dependent 
IF /VF 
 
 
Table 2.B                   
bAll patients on ART were included in descriptive outcomes, but only those with failure were included in analysis  
Reference Study setting and period Design Sample size Inclusion and exclusion criteria (excl.) Criteria for switch to second-line 
Gsponer et al. 2012 (31) Urban Malawi, Zambia, 
hospitals, 2004-2009 
Retrospective 
cohort  
2,411 
(3% of 80,937 on ART) 
- > 16 years  
- IF  
- 50% drop in CD4-peak value / return to ≤ pre-ART CD4 / 
CD4 staying persistently <100 cells/ mm3 
Hosseinipour et al. 2010 
(28) 
Urban Malawi, clinics  
2006 - 2008  
Prospective 
cohort   
 
106 
 (1.3% of 8,000 on ART) 
- > 13 years  
- VL > 400 copies/ml on first-line after suspicion of failure  
excl: declined switch 
Targeted VL > 400 copies/ml  
 
Johnston et al. 2013 
(27)b 
Urban, peri-urban South 
Africa, clinics, initiated  
2003 - 2008 
Retrospective 
cohort  
1,867  
(18% of 10,402 with VL) 
13,537 on ART 
-  15 years  
-  6 mo FU 
excl: patients from clinics with < 50 patients 
Routine VL, 2 VL >1000 copies/ml within 9 mo  
Labhardt et al. 2017 (3) Rural Lesotho, clinics  
2014 - 2015  
Prospective 
cohort   
138  
(8.8% of 1,563 with VL) 
-  16 years  
-  6 mo on NNRTI-regimen 
- First VL≥ 80 copies/ml  
excl: 7 days ART interruption in 3 mo 
Routine VL1  80 copies/ml, EAC, VL2 after 3 months  
80 copies/ml 
Lejone et al. 2017 (23) Rural Lesotho, clinics 2014 - 
2015 
Prospective 
cohort  
53 
(28% of 191 with VL) 
- 16 years 
-  6 mo on NNRTI-regimen  
Routine VL1  80 copies/ml, EAC, VL2 after 3 months  
80 copies/ml 
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- First VL≥ 80 copies/ml   
excl: 7 days ART interruption in 3 months 
Murphy et al. 2010 (24) Peri-urban South Africa, 
Hospital  
2004 - 2006  
Prospective 
cohort   
141  - adults  
-1 VL≥ 1000 copies/ml = > 3 months after initiation 
excl: history of mono-or dual therapy  
1 VL≥ 1000 copies/ml > 3 months after initiation & major 
mutation confirmed by genotyping  
 
Petersen et al. 2014 
(26) 
Urban Uganda & South 
Africa, clinics  
Initiated 2002-2011 
Prospective 
cohort   
823  
(10% of 7,975 on ART)  
- on NNRTI-regimen 
- 2 failing VL >16 weeks after initiation 
Routine VL, 2 consecutive VL >1000 copies/ml between 
12-24 wk or >400 copies/ml > 24 wk after initiation 
(≤ 9 mo apart) 
Ramadhani et al. 2016 
(30) 
Tanzania, hospital, 2004 – 
2013  
 
Retrospective 
cohort 
637  - adolescents and adults  
- IF  
- 50% drop in CD4-peak value / return to ≤ pre-ART CD4 / 
CD4 staying persistently <100 cells/ mm3 
Rohr et al. 2016  (25) South Africa, clinics, 2004-
2014  
 
Retrospective 
cohort  
5,895  -  18 years  
- ART-naive at ART start  
- NNRTI-regimen 
- ≥ 12 mo FU 
excl: - switched to second-line before failure  
- failed < 12 mo before database closure 
2 VL≥ 1000 copies/ml within 12 mo > 3 months after 
initiation  
 
SSempijja et al. 2017 
(29) 
Uganda,  
initiated  
2004 – 2013 
Retrospective 
cohort   
124  
(4% of 3,026 on ART) 
- ≥18 years 
-  3 mo NNRTI-regimen before VL   
- 2 VL≥ 1000 copies/ml within 12 mo 
2 VL≥ 1000 copies/ml within 12 mo 
 
Table 2.C                         
c East Africa: Kenya, Uganda, Southern Africa: Malawi, Mozambique, South Africa, Zambia, Zimbabwe, West/Central Africa: Burkina Faso, Democratic Republic of the Congo, Nigeria, Asia: Cambodja, Myanmar, Laos                                              
d Kenya, Nigeria, South Africa, Uganda, Zambia, Zimbabwe  
Reference Study setting and period Design Sample size Inclusion and exclusion criteria (excl.) Criteria for switch to second-line 
Castelnuovo et al. 
2009 (39) 
Urban Uganda,  
referral hospital 
Switched 2004-2005  
Prospective 
cohort  
40  
(110 (5% ART patients) 
switched, first ones 
enrolled)  
-  VL >400 copies/ml twice or VL >400 copies/ml once and 
immunological and/or clinical failure 
- naive to PIs at switch to PI-based regimen  
- present at ≥2 scheduled clinic visits in the past 6 mo 
- residence of Kampala for the past 12 mo 
- written informed consent 
VL confirmed failure after WHO clinical or immunological 
criteria failure 
 
Court et al. 2014 
(43) 
South Africa, hospital   
2003-2011  
Retrospective 
cohort 
274  - ≥ 15 years  
- second-line ART after 2 VL >1000 copies/ml   
-2 VL >1000 copies/ml   
- first-line side effects  
Fox et al. 2010 (44) Urban South Africa, referral 
hospital  
2004 - 2008 
Retrospective 
cohort 
328  
(3% of 9,694 on ART) 
- ≥ 18 years  
- second-line ART after standard first-line ART  
- ≥12 mo FU  
-2 VL >1000 copies/ml   
- first-line side effects 
Johnston et 2012 
(34) 
Urban, peri-urban South 
Africa, clinics, 2003-2010 
Retrospective 
cohort 
417 
(79% of 529 with VL result) 
- ≥ 18 years  
- second-line ART after VL >400 copies/ml  
- ≥15 mo FU 
- treatment failure (2 V≥ 1000 copies/ml, /1 VL ≥ 1000 
copies/ml & 1 VL 400-999 copies/ml / 1 VL 400-999 copies/ml 
& 1 VL ≥400 copies/ml or missing) 
Levison et al. 2011 
(45) 
Peri-urban South Africa, 
clinic  
 
Prospective 
cohort 
202  
(3% of 6,339 on ART, 724 
failure, 315 on second-line) 
-≥ 15 years 
- switch to PI after 2 VL ≥ 1000 copies/ml or last available VL > 
1000 copies/ml  
- ≥ 6 mo potential FU on PI-based regimen  
excl: transferred in, ART non-naieve 
-2 VL ≥ 1000 copies/ml or last available VL > 1000 copies/ml 
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Murphy et al. 2012 
(42) 
Peri-urban 
South Africa, hospital  
Retrospective 
cohort  
136 
(156 on second-line)  
- adult  6mo on second-line ART 
- VL ≥1000 copies/ml on first-line 
- VL ≥1000 copies/ml on first-line 
 
Narainsamy et al. 
2017(46) 
Peri-urban South Africa, 
hospital   
2011-2014 
Retrospective 
cohort 
223 
(238 switched, 6,500 on 
ART) 
- ≥ 18 years  
- switched from NNRTI-based to PI-based regimen after 2 
documented VL ≥ 1000 copies/ml, 2 months apart  
excl: switched after 1 VL, no VL data, switched for side-effects  
-side -effects  
-2 VL ≥ 1000 copies/ml, 2 months apart 
Onyedum et al. 
2013 (37) 
Nigeria, university hospital  Retrospective 
cohort 
186  
(4% of 4229 on ART) 
- ≥ 15 years  
- ≥ 12 mo on PI-based regimen after NNRT-regimen 
excl: transferred in on second-line  
-no data on first-line regimen  
-2 VL ≥ 1000 copies/ml after ≥ 6 mo ART 
- 50% drop in CD4-peak value / return to ≤ pre-ART CD4 / CD4 
staying persistently <100 cells/ mm3 after ≥ 12 mo ART 
- new WHO-stage 3 or 4 OI on ART 
-ART toxicity  
Osinusi-Adekanmbi 
et al. 2014 (40) 
Nigeria, hospital  
2008-2010  
Prospective 
cohort 
73  
(82 switched & screened)  
- >18 years  
- confirmed VL>1000 copies/ml  
- adherence documented >95% in 3 mo before screening 
Excl: -opted out 
- VL undetectable  
- CF, IF or VF, as identified by clinic provider 
Pujades-Rodríguez 
et al. 2010  (35) c 
13 countries, 10 in Africa, 3 
in Asia 
2001-2008 
Retrospective 
cohort 
632 from 27 cohorts (493 
from Africa)  
- ≥ 15 years  
- ART-naive at ART start  
- > 6 mo on second-line PI after NNRT-regimen 
- known sex information 
site-specific  
Schoffelen et al. 
2013 (36) 
Rural South Africa, clinic,  
2004-2010 
Retrospective 
cohort 
210  - ≥ 12 mo on PI-based second-line PI March in March 2004 
- initiated at that clinic  
- VL ≥ 1000 copies/ml after suppression < 400 copies/ml - 
con’d VL > 400 copies/ml after 6 months on ART 
- adverse effects on first-line  
Shearer et al. 2017  
(47) 
Urban South Africa, clinics  
 
Retrospective 
cohort  
1,236 - >18 years  
- ART naïve at initiation on first-line ART  
- start second-line ART < 1 year after VF 
excl: - on second-line ART during pregnancy  
- switched to second-line without evidence of failure 
- 2 consecutive VL >1000 copies/ml (2 weeks to 6 months 
apart), ≥ 4 months after initiation  
Sigaloff et al. 2012 
(38) d 
6 African countries  
2007 – 2009  
Prospective 
cohort 
243  
(232 with genotyping result)  
- switched to second-line ART after VF, IF or CF 
excl: on PI before switch, pregnant 
-site specific  
 
Tsegaya et al. 2016 
(41) 
Ethiopia, hospital  
2006 - 2015  
Retrospective 
cohort 
356  - ≥ 15 years  
- initiated second-line ART at that clinic 
- ≥ 6 mo on second-line 
- VL failure after suspicion of failure  
- varying definitions of VL failure over time  
Wilhelmson et al. 
2016 (33) 
Ethiopia, hospital,  
2014 - 2016 
Retrospective 
cohort  
383 (out of 427 eligible) - PI-based second-line ART after NNRTI-based first-line 
excl: - documented transfer  
- initiated second-line in another clinic  
- missing data 
Clinical and/or immunological criteria (new HIV-related 
conditions or absence of CD4 cell response) for suspected first-
line ART failure, since 2010 confirmed with VL testing 
Or first-line side-effects 
ART= anti-retroviral treatment, CF = clinical failure, excl.: exclusion criteria, FU = follow-up, IF = immunological failure, ml = millilitre, mo = month/s, NRTI = nucleotide reverse-transcriptase inhibitor, NNRTI = non-
nucleotide reverse-transcriptase inhibitor, OI = opportunistic Infection, PI = protease-inhibitor, RIC = retention (retained) in care, VF = virologic failure, VL = viral load, wk = week/s, WHO = World Health Organisation
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Table 3: Characteristics of included patients  
A: Characteristics of patients who experience first-line failure (at failure, unless specified) 
B: Characteristics of patients who are switched to second-line ART (at switch, unless specified) 
Table 3.A: Characteristics of patients who experience first-line failure (at failure, unless specified) 
Reference Female 
sex (N, %) 
Age (yrs) 
(median, IQR) 
CD4-count 
(cells/mm3)  
VL (Log 10 copies/ml) 
(median, IQR) or (N, %) 
Time on ART  
(median, IQR) 
First-line regimen  Second-line regimen  WHO-stage  
Barth et al. 2011 (19)a 223 (66%) at ART start: 35 
(mean) 
at ART start: 54 at ART start: 
4.9 (mean) 
24-36 mo: 162 (48%) 
36-48 mo: 111 (33%) 
>48 mo: 60 (18%) 
EFV: 204 (61%) 
d4T: 253 (76%) 
  
Gsponer et al. 2012 (31) 1276 
(53%) 
29 (25-34) 
at ART start: 27 (23-
32) 
<50: 325 (13%) 
50-99: 585 (24%) 
100-199: 763 (32%) 
≥200: 738 (31%) 
NR NR AZT/3TC + NVP: 1215 (50%),  
+ EFV: 97 (4%) 
d4T/3TC +NVP: 1005 (42%),  
+ EFV: 89 (4%)  
TDF/FTC/LPV: 194 (60%)  
ABC/ddI/LPV: 65 (20%) 
AZT/TDF/FTC/LPV: 15 (5%)  
AZT/TDF/FTC/LPV/r: 14 (4%)  
at ART start:  
I/II: 644(27%)  
III/IV: 1767 
(73%) 
Hosseinipour et al. 2010 
(28) 
 59 (54%) 38 (32-46) at switch (n=101):  
65 (22–173)  
at switch (n=101):  
4.7 (4.2– 5.2)  
34 (25–48 ) mo 
at switch: 35 (25-49) 
EFV or NVP / 3TC /  
d4T or AZT 
LPV/r based 
Johnston et al. 2013 
(27) 
503 (27%) 42 (17-71) (mean, 
range) 
184 (108-279) 4.3 (3.0-5.7) (mean, 
range) 
17 (13-24) yrs 
 
AZT/3TC/NVP or EFV 
TDF/FTC/EFV  
d4T/3TC/EFV or NVP 
ABC/ddI/LPV/r  
AZT/ddI/LPV/r 
 
Keiser et al. 2011 (22) 473 (67%) at ART start:  
Switched (n=382): 
35 (30-41)  
Not switched 
(n=323): 34 (30-40) 
at ART start:  
Switched (n=282): 73 
(23-133)  
Not switched (n=259): 
67 (21-161) 
at ART start:  
Switched (n=73): 5.0 
(4.4-5.6)  
Not switched (n=64): 
5.3 (4.6-5.8) 
At switch:  
17 (11- 25) mo  
AZT/ddI/NVP: 296 (42%) 
d4T/3TC/EFV: 221 (31%)  
AZT/3TC/NVP: 74 (10%)  
AZT/3TC/EFV: 74 (10%)  
AZT/ddI/LPV/r: 171 (45%) 
ABC/ddI/LPV/r: 42 (11%)  
AZT/3TC/LPV/r: 33 (9%)  
TDF/FTC/LPV/r: 23 (6%)  
d4T/ddI/ LPV/r: 18 (25%)  
at ART start: 
III/IV: 282 
(40%)  
Labhardt et al. 2017 (3) 91 (66%) 
 
41 (32–50) 351 (182–520)  
 
3.9 (3.2–4.3)  49 (29–68) mo 
 
 
AZT/3TC: 70 (51%) 
TDF/3TC: 67 (49%)  
ABC/3TC: 1 (1%)  
NVP: 90 (65%), EFV: 48 (35%) 
TDF/3TC/LPV/r 
AZT/3TC/LPV/r 
ABC/3TC/LPV/r 
RAL/LPV/r 
 
Lejone et al. 2017 (23) 25 (47%) 9.7 (5.6–13.0)  
At start: 5.1 (1.6-
8.5) 
41 5 yrs:  
690 (432-1015)  
12<5yrs CD4 %: 
22 (17–32)  
 44 (25–58) mo AZT/3TC: 47 (89%) 
TDF/3TC: 2 (4%) 
ABC/3TC: 4 (8%) 
NVP: 14 (26%), EFV: 36 (68%),  
TDF/3TC/LPV/r 
AZT/3TC/LPV/r 
ABC/3TC/LPV/r 
LPV: 3 (6%) 
  
Murphy et al. 2010 (24) 71 (50%) 36 (30-42) (n=122 
with mutation)  
43 (35-47) (n=19) 
≥ 100:110 (78%) 
<100: 29 (21%) 
≥5: 27(19%) 
<5: 113 (81%) 
13 (7-20) (n=122 with 
mutation) mo 
8 (6-12) (n=19) mo  
AZT/3TC + NVP: 17 (12%), + EFV: 38 (27%) 
d4T/3TC/NVP: 9 (6%) + EFV:61 (43%) 
d4T/ddi/EFV : 2 (1%) 
I/II: 47 (33%)  
II/IV: 64 (45%) 
Petersen et al. 2014 
(26) 
562 (68%) <30: 228 (28%) 
30-39: 396 (48%) 
≥40: 199(24%) 
<100: 114 (14%) 
100-199: 244 (30%) 
200-349: 319 (39%) 
350-499: 108 (13%) 
≥500: 38 (5%) 
<0: 103 (13%) 
0-3.7 269 (33%) 
3.7-4: 97 (12%) 
4-5: 263 (32%) 
>5: 91 (11%) 
17 (10--31) yrs EFV: 428 (52%) 
NVP: 395 (48%) 
 At ART start:  
I/II: 215 (26%)  
III/IV: 566 
(69%) 
Ramadhani et al. 2016 
(30) 
394 (62%) <30: 134 (21%) 
30-55: 454 (71%) 
≥55: 49 (8%) 
At switch (n = 396)  
<100: 174 (44%) 
100-200: 166 (42%), >200: 56 (14%) 
<36 mo: 360 (57%)  
36-60 mo: 187 (29%) 
>60 mo: 90 (14%)  
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Table 3.B: Characteristics of patients who are switched to second-line ART (at switch, unless specified)  
Reference Female 
(N, %) 
Age (yrs) 
(median, IQR) 
CD4-count 
(cells/mm3)  
VL (Log 10 copies/ml) 
(median, IQR) or (N, %) 
Time on ART 
(median, IQR) 
First-line regimen  Second-line regimen  WHO stage 
Castelnuovo et al. 2009 (39) 20 (50%) 39 (36-43) 108 (43-205) 4.8 (4.0-5.4)  22 (19-29) mo d4T/3TC or AZT/3TC 
EFV or NVP 
AZT/ddI/LPV/r: 36 (90%) 
d4T/ddI/LPV/r: 4 (10%) 
II: 7 (17%) 
III: 14 (35%), IV: 19 (48%)  
Court et al. 2014 (43) 149 (55%) 35 (32-42) At ART start: 174 (107-
265) 
At ART start: 4.1 (3.6 
-4.7) 
27 (15-47) mo    
Fox et al. 2010 (44) 216 (66%) 37 (8) (mean, SD) 203 (128) (mean, SD)  38 (8) (mean, SD) 
mo  
d4T/3TC/EFV: 259 (79%) 
d4T/3TC/NVP: 46 (14%) 
  
Hawkins et al. 2017 (21) 1144 (65%) 40 (10) (mean, SD) 
 
239 (205) (mean, SD) 4.4 (1.1) (mean, SD) 34 (17) (mean, SD) 
mo 
NR ABC/3TC(FTC)/PI: 35 (2%) 
ABC/ddI/PI: 1232 (70%) 
TDF/3TC (FTC)/PI: 405 (23%) 
Other+PI: 70 (4%) 
I: 53 (3%)  
II: 141 (8%) 
III: 1074 (61%) 
IV: 493 (28%) 
Johnston et al.  2012 (34) 
workplace (n=205) 
17 (8%) 43 (37-49) 169 (97-235) 
At ART start:166 (91-221)  
4.6 (4.1-5.1) 22 (15-34) mo  NR No new NRTI: 14 (7%), 1: 7 
(3%), ≥2: 184 (90%) 
At ART start:  
III/IV: 108 (71%) 
community (n=212) 130 (61%) 36 (31-42) 187 (95-270) 
At ART start:122 (43-195)   
4.3 (3.7-4.6) 17 (10-25) mo  NR No new NRTI: 26 (12%), 
1 : 46 (22%), ≥2 : 140 (66%) 
At ART start: 
III/IV: 164 (86%) 
Levison et al. 2011 (45) 153 (75%) 34 (7) (mean, SD) 212 (133-289) 4.0 (3.6-4.4) at failure: 11 (7-18 ) mo   
Murphy et al. 2012 (42) 88 (65%) 36 (31-43) 153 (89-232) 
at ART start: 70 (20-118)  
 
4.4 (3.8-4.9) 13 (7-20) mo   AZT/ddI/PI 88 (65%) 
AZT/3TC/PI: 30 (22%)        
3TC/PI alone: 7 (5%)  
d4T/3TC/PI: 6 (4%) 
 
Narainsamy et al. 2017 (46) 152 (68%) at ART start 
18-29: 35 (16%) 
30-39: 103 (46%) 
40-49: 66 (30%) 
>49: 19 (9%) 
at ART start:  
0-100: 131 (60%)  
101-200: 65 (30%)  
>200: 23 (11%) 
<4: 45 (20%) 
4-5: 117 (53%)  
>5: 61 (27%) 
NR TDF/3TC + EFV: 68 (31%), + NVP 40 (18%)  
AZT/3TC + EFV : 6 (3%), + NVP : 8 (4%)  
d4T/3TC +EFV : 55 (25%) + NVP : 45 (21%)  
ABC/3TC/EFV : 1 (0%)  
 
Onyedum et al. 2013 (37) 110 (59%) 42 (10) (mean, SD) At ART start:  
<200: 112 (60%)  
200-499: 63 (34%)  
≥500: 11 (6%) 
at ART start: 4.5 (3.9-
6.3) 
17 (8) mo (mean, 
SD) 
d4T/3TC/NVP: 121 (65%) 
AZT/3TC/NVP : 41 (22%)  
TDF/FTC/NVP: 11 (6%) 
TDF/FTC/EFV: 7 (4%) 
TDF/3TC/AZT/LPV/r: 186 
(100%)  
 
Osinusi-Adekanmbi et al. 
2014 (40) 
49 (67%)  35 (30-41) 121  24 (16-32) mo TDF: 26 (37%) 
AZT/d4T: 45 (64%) 
  
Pujades-Rodríguez et al. 
2010  (35) 
380.9 pyr FU 
(63%) 
35 (30-42) <50: 126 pyr 
50-99: 115 pyr 
100-199: 172 pyr 
≥200: 196 pyr 
 24 (16-31) mo D4T : 445 pyr 
AZT : 165 pyr  
EFV : 146 pyr 
NVP : 463 pyr 
LPV/r: 374 pyr  
NFV: 463 pyr  
I/II: 63 pyr (43%) 
III/IV: 85 pyr (57%) 
 
Schoffelen et al. 2013 (36) 145 (69%) 
 
 
33 (24-40) 
39 (19%) of <15 
years 
Adults: 187 (93-299) 
Children: 485 (308-983) 
 
At ART start:  
Adults: 62 (18-139) 
4.0 (3.4-4.5) 19 (11-31) mo d4T/3TC: 146 (70%) 
AZT/3TC: 61 (29%) 
TDF/3TC: 1 (1%) 
NVP: 112 (53%) 
EFV: 96 (46%) 
 
AZT/3TC/LPV/r: 151 (72%) 
TDF/3TC/LPV/r: 28 (13%) 
d4T/3TC/LPV/r: 10 (5%) 
TDF/FTC/LPV/r : 2 (1%) 
ABC/3TC/ LPV/r: 1 (1%) 
other/LPV/r:18 (9%) 
 
Shearer et al. 2017  (47) 731 (59%) 38 (33–44) 203 (114–305)  4.2 (3.6–4.8) 19 (13–31) mo TDF/3TC/EFV : 217 (18%) 
d4T/3TC/EFV: 827 (67%) 
Other: 192 (16%) 
TDF/3TC(FTC)/LPVr : 374 (30%) 
AZT/3TC/LPVr: 366 (30%) 
AZT/ddI/LPVr: 496 (40%) 
 
Sigaloff et al. 2012 (38) 116 (50%) 38(34-45) 126 (66-205) 4.2 (3.3-5.0) 27 (15-44) mo AZT/3TC/NNRTI: 12 (44%)   
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3TC = lamivudine, ABC = abacavir, ART= anti-retroviral treatment, AZT =zidovudine, d4T = stavudine, ddI = didanosine, EFV = efavirenz, FTC = emtricitabine, FU = follow-up, IQR = interquartile range, LPV = lopinavir, 
LPV/r = lopinavir/ritonavir, ml = millilitre, NRTI = nucleotide reverse-transcriptase inhibitor, NNRTI = non-nucleotide reverse-transcriptase inhibitor, NVP = nevirapine, OI = opportunistic Infection, PI = protease-
inhibitor, RAL = raltegravir, RIC = retention (retained) in care, SD= standard deviation, TDF = tenofovir, VF = virologic failure, VL = viral load. WHO = World Health Organisation, yrs = years  
D4T/3TC/NNRTI : 95 (41%) 
TDF/FTC/NNRTI : 23 (10%) 
Triple NNRTI :  4 (2%) 
Tsegaya et al. 2016 (41) 158 (44%) 15-29: 78 (22%) 
30-39: 167 (47%) 
40-49: 82 (23%) 
>50: 29 (8%) 
<100: 222 (62%) 
≥ 100: 134 (38%)  
 43 (26-64) mo TDF: 206 (58%) 
ABC: 102 (29%)  
AZT: 41 (12%)  
d4T/ddi : 7 (2%) 
LPV/r : 289 (81%) 
ATV/r : 64 (18%) 
NFV: 3 (0%)  
I/II: 127 (36%) 
III: 172 (48%) 
IV: 57 (16%) 
Wilhelmson et al. 2016 (33):   
adults (n=330) 
180 (55%) 37 (30-42)  
 
126 (66- 226)  
 
4.9 (4.5-5.3) 
 
   I/II: 109 (33%) 
III/IV: 216 (65.5%)  
 <15 yrs (n=53)  27 (51%) 11 (7-14)  154 (88-319) 5.0 (4.6-5.5)     
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Outcomes  
Access to viral load testing and cascade after first-line failure 
Table 4 presents steps in the cascade after first-line failure. The proportions of patients with 
a VL done can only be compared between settings with similar access to VL testing. VL 
testing coverage ranged from 13% (no routine VL; 82% had CD4 results) (21), to 77%  
(routine VL (27)). Median time between first high VL and a confirmatory test was reported 
by five studies, and ranged between 2.6 (IQR, 1.8-3.8) (26) and 6.8 (IQR, 0.1-32) months 
(46), the latter being a small study in a single clinic (46). A larger study in Uganda also 
reported 5.6 months (5.1-5.6) as a median, however this might have been influenced by the 
fact that routine VL was being introduced during the study (29). These results reflect 
guideline recommendations that varied between 3-6 months between first and second VL. 
Proportions of patients with confirmed treatment failure out of all on ART varied from 1%  
(targeted VL setting) to 16% (routine VL), with higher proportions in studies with longer 
follow-up (19,28). The proportions found seem consistent with systematic reviews reporting 
>80% on treatment viral suppression in LMIC (48), using thresholds between 300 and 500 
copies/ml (49). Reported proportions with VF were lower if only targeted VL testing was 
used (28) or VL was still being scaled up (22,29). Proportions switched to second-line among 
failing patients were reported by eight studies, varying between 30% at six months after 
failure (26,29), 13-45% at 12 months (27,29), 62-73% around 18 months (3,30), and 65% at 2 
years (29). Most studies with higher proportions switched were those requiring a 
confirmatory VL or genotyping to define failure (3,24,25,29), and lower proportions where 
reported when relying on immunological criteria only (31). Time from FEVL or from failure to 
switch ranged between 1.9 (IQR, 0.9-4.6) (47) and 36 (IQR, 18-54) months (20). Two studies 
with low switch proportions and long delays reported reluctance of clinicians to switch, for 
fear of wasting the regimens due to poor adherence (19–21,27).   
Mortality  
Reported mortality after treatment failure ranges between 4% (2) at 18 and 14% (25) at 12 
months (23,28). After second-line switch, reported mortality ranged from 1% at 2 years (42) 
to 10% after one year (28).  One systematic review, considered mortality up to 11% by 12 
months after switch as low (12). With this criterion, mortality after failure and after switch 
in the included cohorts is overall low (below 10%). One exception is the Malawi cohort (28), 
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where 14% of those with failure and 10% of patients on second-line died. The latter died in 
the first six months (six in the first three months) after switch. Early mortality is common 
when patients present with advanced stage of disease and/or low CD4-counts (19,28).  
Loss-to-follow-up and retention in care  
Loss-to follow-up (LTFU) was defined and reported inconsistently, with different definitions 
(Table 5). After treatment failure, authors report LTFU of 9% at six months (24), 21% at 18 
months (3) and 60% by the end of follow-up (follow-up time not reported) (25). Six months 
after second-line switch, authors report LTFU between 4% (14) and 17% (44). 12 to 18 
months after switch, LTFU ranged between 3% (42) and 15% (23,34). Retention in care after 
switch was reported by eight studies, reporting 83%-92% at six months (43,45), 83-93% at 
12 months (42,43), and 53% at 24 months to (43) 81% (33) at 22 (median) months. 
Systematic review data from sub-Saharan Africa from 2010 reported a mean retention on 
first-line ART of 65% at three years (50). More recent articles indicate it might be lower in 
growing cohorts needing long-term retention after ART start (4). In our studies, after 
treatment failure, LTFU was highest in Lesotho (21%) at 18 months (3) and in a long-term 
(>10 years) study in South Africa, where 60% of patients left the cohorts through LTFU. LTFU 
after switch was 30% in the same study,  with a median follow-up after switch of 17 months 
(IQR, 9-29) (25). One other study in South Africa reported 31% LTFU in a cohort with a 
median follow-up of 24 months (IQR, 14-36). Like in other studies (12,35,40), patients with 
high VL and low CD4 were more likely to be lost, and LTFU is thus likely to mask mortality 
(47).  
Virologic Outcomes  
Of patients who failed first-line, reported re-suppression proportions were between 19% (in 
children), and 85% (adults) at one year after failure (3,23,28). After switch, proportions re-
suppressing varied between 41%-79% (24,37) 46%-87% (25,34,38) at 6 and 12 months post-
switch respectively, with similar results at longer durations These results are consistent with 
systematic review data in LMIC in which pooled estimates were 22% and 23% virologic 
failure at six and 12 months on second-line ART (12). Pujades-Rodriguez report only 2% 
immuno-virologic failure but 12% of any failure after switch (14). Lejone et al. reported only 
38% re-suppression (VL≤80 copies/ml) 18 months after switch in children in Lesotho (23). 
One study reported a virologic increase (in 0.5 log10 VL versus VL at failure) of 9/100 pyr 
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after 2 years (38). The one study  which reported over 90% re-suppression used genotyping 
to investigate drug-resistance and guide choice of second-line regimens (24). Particularly 
low re-suppression rates (<50%) were found in Lesotho (3,23) and in one study in South 
Africa (45). The Lesotho studies had small sample sizes, and a weak health system and a 
reluctance to switch patients according to the defined criteria, in this decentralised nurse-
led programme, were given as reasons for poor outcomes (3). Only 38% of children in the 
Lesotho cohort re-suppressed at 12 months, but many retained the same NRTI on second-
line, which might be have been sub-optimal (23). This result is worse than a multicenter 
analysis in LMIC, in which only 16.4% of children had virologic failure 2 years after switch 
(13). 
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Table 4: The cascade from ART initiation until re-suppression on second-line ART  
a First-line failure = VF unless specified. All time measured are presented in months. Denominator for first-line failure is all on ART, unless specified. Denominator for switched is those with failure, unless specified.   
Reference Total on ART VL done (CD4) Months VL1-VL2  First-line failure a  Switched  Months failure-switch Re-suppressed after switch 
Barth et al. 2011 (19) 735   117 (16%) 31 (26%)  25/31 (81%)  
Boulle et al. 2010 (18) 7,323   14% (at 5 yrs) 12.2% all (at 5 yrs) 5.3 (2.2-11.2)  22/29 (76%) at 5 yrs  
Castelnuovo et al. 2009 (39) 2,340    110 (5%) all 9 (3-11) from VL1 75% at 12 mo (ITT) 
Court et al. 2014 (43)     274  169/228 (86%) at 12 mo 
De Beaudrap et al. 2013 (20) 366   79/324 (24% VS) 65 (18%) (48 VF) 36 (18-54) from VL1 43/53 (81%) (median FO 6 mo) 
Fox et al. 2010 (44) 10,022    328 (3%) all 2.8 (1.1-6.1)  203/262 (77%) at 12 mo 
Gsponer et al. 2012 (31) 80,937 655 (27%)  IF: 2,411 (3%) 324 (13%)   
Hawkins et al. 2017 (21) 47,296 5,949 (13%) (39,490 (82%))  VF: 1,459 (3%), IF: 7,825 (17%) 1760 15.6 (13.2) (mean, SD)  
Hosseinipour et al. 2010 (28) ~8,000   109 (1%) 101 (93%)  85% of 101 at 12 mo  
Johnston et al. 2013 (27) 13,537 10,402 (77%) 4.9 (2.8-6.1) 1,867 (13%), 18% of VL 361 (22%) of incl.  291/361 (81%) end FU 
Johnston et al. 2012 (34)  14,779    529 (4%) all  250/330 (76%) at 15 mo 
Keiser et al. 2011 (22) 16,591   705 (4%) VF, IF or CF 382 (54%)   
Labhardt et al. 2017 (3)  1,563 (VL1, 9% high)   80 (5%), (69%) of 116 VL2 58 (73%)   32/58 (55%) at 12 mo  
Lejone et al. 2017 (23).   191 (VL1, 28% high)  36 (19%), (74%) of 49 VL2 24 (67%)  9/24 (38%) at 12 mo 
Levison et al. 2011 (45) 6,339   724 (11%) 315 (44%) 5 (3-8)  85/167 (51%) at 6 mo 
Murphy et al. 2010 (24)    141  107 (76%)  100 (93%) at  6 mo 
Murphy et al. 2012 (42)     136  94/126 (75%) at 12 mo 
Narainsamy et al. 2017 (46)   6.8 (0.1-32)  238  6.4 (0-43.3)  176/223 (79%) at 18 mo  
Onyedum et al. 2013 (37) 4,229     186 (4%) all  56 (82%) at 12 mo 
Osinusi-Adekanmbi et al. 2014 (40)     73   48 (66%) at 12 mo  
Petersen et al. 2014 (26) 7,975  2.6 (1.8-3.8)  823 (10%) 358 (43%) 3.9 (2.1-6.6)   
Pujades-Rodríguez et al. 2010  (35)     632  507 (81%) (med FU 12 mo) 
Ramadhani et al. 2016 (30)    IF: 637 396 (62%) (233) 59% < 3 mo  
Rohr et al. 2016  (25)   2.9 (1.9-4.9)  5,895 3,706 (63%) 3.4 (11-8.7) 14% VF (med FU 17 mo) 
Schoffelen et al. 2013 (36)     210  6 (3-11)  92/128 (72%) at 12 mo 
Shearer et al. 2017  (47)     1,236  1.9 (0.9-4.6)  75% at 12mo 
Sigaloff et al. 2012 (38)     243   180/208 (87%) at 12 mo 
SSempijja et al. 2017 (29)  3,036  5.6 (5.1-5.6)  124 (4%) 82 (66%) 8.1 (3.7-17.0)   
Tsegaya et al. 2016 (41)     365  289 (79%)  (median FU 32 mo) 
ART = antiretroviral therapy, FU= follow-up, IF = immunological failure, ITT= intention-to-treat, mo = month/s, SD = standard deviation, VL= viral load, VL1 = first high VL, VL2 = confirmatory VL, VF = virologic failure, 
VS= virologic success
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Table 5: Outcomes  
A. After treatment failure on first-line ART  
B. After switch to second-line ART 
Table 5.A: Outcomes after treatment failure on first-line treatment  
aRe-suppression means viralogical suppression on second-line or overall, unless specified that it is first-line.  
Reference Follow-up period 
After failure  
Mortality Virologicala 
(VL in copies/ml) 
Immunological 
(CD4 in cells/mm3) 
LTFU/RIC Switch  Other outcome/ 
Comments  
Gsponer et al. 2012 (31) 3932 pyr 76 (3%) 
19 (15-24)/1000 pyr 
  177 (7%) LTFU  
55(37-52)/1000 pyr 
324 (13%) 
82 (74-92) /1000 pyr 
LTFU: not returning ≥ 12 mo 
Hosseinipour et al. 2010 (28) 12 mo 15 (14%) re-sup: 85%  
(13 others: 6 never sup, 
7 rebound) 
CD4 increase: 142    re-sup: VL <400 copies/ml 
Johnston et al. 2013 (27) 19 (10-5) mo 107 (6%)  296 (18%) re-sup on 
first-line  
 312 (19%) LTFU  
49 (3%) TO 
67 (4%) left  
476 (29%) admin cens 
361 (22%)  Denominator: 1921.8 pyr failure 
LTFU= no clinic contact > 6 mo 
re-sup: VL <400 copies/ml  
 12 mo 5%  13%  re-sup on first-line   17%  Cumulative incidence/ Competing Risks   
Keiser et al. 2011 (22) Cum 12 mo: 
4% second-line   (5/100 pyr) 
2% non-failing first-line (3/100 pyr) 
12% on failing first-line (13/100 pyr) 
 LTFU per 100 pyr: 
5 second-line   
2 non-failing first-line 
14 failing first-line 
 LTFU: >1 yr between last visit and cohort 
closure  
Labhardt et al. 2017  (3) 18 mo 10 (7%) 56 (58%) re-sup  29 (21%) LTFU 58/80 (73%)  LTFU: status unknown 
re-sup: VL<80 copies/ml Lejone et al. 2017 (23) 18 mo 2 (4%) 10 (19%) re-sup  8 (15%) LTFU 24/36 (67%) 
Murphy et al. 2010 (24) 6 mo 6% (2-9) 99 (70%) <400 
copies/ml 
91 (65%) <50 copies/ml  
50%: 30% CD4-increase  
Med increase: 88 (7-168)  
Med CD4: 249 (166-343)  
33% had CD4 <200 
9% (4-13) LTFU   
Petersen et al. 2014 (26) med 25 mo 49 (6%) 
2.5/1000 pyr 
  
 
1, 3, 6 mo: 
3%, 16%, 30% 
 
Ramadhani et al. 2016 (30) med 17 (8-32) mo     396 (62%) OI: TB, pneumonia, KS, CM, HZ  
OI: 115 (18%), 7% pneumonia, 6% TB 
Rohr et al. 2016  (25) end FU: max 10 yrs  298 (5%) end FU   3555 (60%) LTFU  
2042 (35%) RIC  
3706 (63%)  
SSempijja et al. 2017 (29) 24 mo 8 (7%) Vir increase:  
24/270 pyr 
9/100 pyr  
Imm decline: 30/259 pyr 
12/100 pyr 
 49/100 pyr 
second-line   
30.2%, 44.6%, 65.0% 
at 6,12,24 mo 
Imm decline: to 50 from CD4 at failure  
Vir increase: to 0.5 log10 from VL at failure  
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Table 5.B: Outcomes after second-line switch  
Reference Follow-up period 
after switch 
Mortality Virologic  Immunological 
(CD4 in cells/mm3) 
LTFU/RIC Clinical  Other outcome/ 
Comments  
Barth et al. 2011 (19) 24-48 (since ART) mo  Re-sup 25/31 (81%)                    re-sup: <50 copies/ml 
Boulle et al. 2010 (18) 150 (since ART) mo  Re-sup 22/29 (76%)     re-sup: VL <400 copies/ml 
Castelnuovo et al. 2009 
(39) 
36 mo 1 (3%) (2 we)  ITT: 12,24,36 mo:  
75%, 85%, 82% re-sup 
3 VF at 36 mo 
Med CD4: 279 (239-461) 
Med increase: 214 (128-
295) 
 25 (62%) toxicity 40 patients, failure; VL>400 copies/ml 
Adherence >95 % at 12, 24, 36 mo: 
92%, 97%, 97% 
Court et al. 2014 (43) med 27 mo VL at 6, 12, 18, 24, 30, 36, 42, 48  mo (% of VL results).   
VL<50: 
159 (71%), 155 (79%), 115 (72%), 97 (78%), 77 (79%), 58 (74%), 48 (70%), 33 (73%) 
VL < 400:  
195 (87%), 169 (86%), 132 (83%), 107(86%), 88(91%), 69(88%), 60(87%), 40(89%) 
VL ≥1000:  
22 (10%), 26 (13%), 26 (16%), 16 (13%), 7 (7%), 7 (9%), 2 (3%), 4 (8%) 
RIC at 6, 12, 18, 24, 30, 
36, 42, 48 mo:  
252 (92%), 228 (83%), 
180 (66%), 146 (53%), 
112(41%), 87(32%), 
72(26%), 54(20%) 
  
  
De Beaudrap et al. 2013 
(20) 
45 (since ART) mo  6 mo: 43 (81%) VL <500 
copies/ml 
6, 12, 24 mo: 18%, 20%, 27% VF 
   12 relapsed after resupression: 
all 12 patients has dual class resistance 
8 were resistant to second-line drug 
VF : 2x 1000 copies/ml 
Fox et al. 2010 (44) 12 mo 17 (5%) after 4 mo (1-
8) 
262 (81%) VL done 
203 (77%) Re-sup at 12 mo,  
(18 (9%) rebound) 
Med increase   
6 mo: 59 (37-80) 
12 mo: 133 (106-160) 
 
243 (78%) RIC 
53 (17%) LTFU after 6 
mo (4-9) 
15 TO (excluded) 
 Compared to first-line outcomes, second-
line were slightly less likely to be RIC 
re-sup: VL<400 copies/ml 
Hawkins et al. 2017 (21)  2.4/100pyr    9.0 /100 pyr   LTFU: >90 days since last clinic visit, no 
contact >120 days before cut-off or death 
Hosseinipour et al. 2010 
(28) 
12 mo  10 (10%) 75% alive re-sup   34 (34%): HIV-
events  
(N=101) 
re-sup: VL <400 copies/ml 
Johnston et al. 2012 
(34)  
15 mo 
 
 
 
 
12 mo 
12 (6%) workplace 
12(6%) community 
Workplace: VS 89 (48%), 26% 
rebound 
Community: VS 152 (72%), 
13% rebound  
Med 5 VL done  
Workplace: VS: 59 (46%) 
Community VS: 116 (72%) 
Med increase:  
68 (40-95) workplace 
127 (101-154) community  
Workplace: RIC 179 
(74%),  LTFU: 29 (14%) 
Community: RIC 151 
(84%), LTFU: 15 (7%), 
TO: 5 (3%)  
 
 VS= VL <400 copies/ml  
Labhardt et al. 2017  (3) 18 mo 2 (3%) 32 (55%) re-sup  8 (14%) LTFU  (n=58) re-sup: VL<80 copies/ml 
Lejone et al. 2017 (23). 18 mo 1 (4%) 9 (38%) re-sup  8 (15%) LTFU  (n=24) re-sup: VL<80 copies/ml 
Levison et al. 2011 (45) 6 mo 4 (2%) VL >400: 82 (41%)  Med increase: 90 (-4-177) 7 (4%) TO 
24 (12%)  LTFU  
167 (83%) RIC 
  
Murphy et al. 2010 (24) 6 mo  70 (41%) re-sup    (N =107), re-sup:VL <400 copies/ml 
Murphy et al. 2012 (42) 24 mo 1 (1%) VL >1000  at 6, 12, 18, 24 mo:  Med CD4 at 6, 12, 18, 24 
mo: 228 (157–329, 276 
RIC 6, 12, 18, 24 mo  
136 (100%) 126 (93%) 112 (82%)  99 (73%) 
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36 (26%),32 (25%) 23 (21%),  
25 (25%) 
(201–404),  315 (207–436), 
330 (230–481) 
LTFU: N/A, 4 (3%), 11 (9%), 17 (15%) 
TO: N/A, 6 (4%), 13 (10%), 19 (17%) 
Narainsamy et al. 2017 (46) 18 mo  47 (21%) VF    VF: VL>1000 copies/ml 
Onyedum et al. 2013 (37) 12 mo  re-sup: 3, 6, 12 mo: 93 (82%), 
70 (79%), 56 (82%)  
IS 3, 6, 12 mo: 91 (56%), 
107 (71%), 81 (79%) 
  re-sup= <400 copies/ml  after switch 
IS = increase ≥50% vs CD4 at switch 
Osinusi-Adekanmbi et al. 
2014 (40) 
>24 mo 5 (7%) VS at 6-9, 12, 12-24, >24 mo: 
OT: 88%, 91%, 91%, 91% 
ITT: 73%, 66%, 58%, 58% 
 LTFU: 6 (8%) 
Withdrew 5 (7%)  
 VS: VL <1000 copies/ml 
Pujades-Rodríguez et al. 
2010  (35) 
741 pyr 34 (5%) at 15 (12-26 mo) 
At 30 mo: 44/1000 pyr 
I/VF:12, 24 mo: 2%, 8%, any failure: 12%,18% 
53, 46 1000 pyr 
23 (4%) LTFU at 6 mo 
At 30 no: 33/1000 pyr 
 Any failure: 12mo, 24 mo: 12%, 28% 
119 (19%) at 12 (9-17mo) 
Rohr et al. 2016  (25) med 17 (9-29) mo 2%  14% VF  42% RIC without VF 
30% LTFU  
 (n=3706 ) VF: 2x VL>1000copies/ml 
LTFU last visit > 6 mo before cut-off 
Schoffelen et al. 2013 (36) 20 (11-35) mo 11 (6%) of which 6 in first 
12 mo  
En of FU: VS: 111 (58%) 
VL 6,12,18,24 mo:  
VL <400: 95 (71%), 92 (72%), 
82 (69%), 63 (75%) 
VL<50: 74 (55%), 78 (61%), 70 
(59%), 54 (64%) 
Increase: ad: 152(-4-398) 
Child: 27 (-172-210) 
RIC:  139 (73%) 
15 (8%) TO 
24% CF VS: VL <50 copies/ml 
VL Cross-sectional data 
Shearer et al. 2017  (47) 12 mo 22 (2%)  75% re-sup 12 mo   123 (11%) LTFU   LTFU: ≥ 3 mo late for scheduled visit 
  med 24 (14-36) mo 14% end FU   31% LTFU end FU   re-sup: ≥ 400 copies/ml 
Sigaloff et al. 2012 (38) 12 mo 11 (5%) 201 VL results  
28 (14%) VF  
180 (87%) re-sup  
21 (12%) IF  208 RIC (90%), 19 (8%) 
LTFU, 4 (2%) TO 
WHO stage IV/TB : 
13 (6%) CF  
LTFU (no def) 
VF ≥ 400 copies/ml after switch 
Tsegaya et al. 2016 (41) med 32 (15-53) mo 
1085 pyr 
21 (6%)  24 (7%) IF 11 (3%) LTFU 11 (3%) CF Overall failure (death, IF, CF, LTFU): 
67 (19%) or 62/1000 pyr 
Cum inc: 12, 24, 60, 96 mo: 
65, 14%, 24%, 42%) 
LTFU: no ART for ≥ 3 mo, no info 
Wilhelmson et al. 2016 (7) med 22 mo 
ad: 22 mo 
child: 24 mo 
 
ad: 2(1%) 
child: 0 (0%) 
 81% RIC, 19% LTFU 
ad: 256 (80%) RIC, 63 (20%) LTFU, 9 TO 
child: 42 (86%) RIC, 7 (14%) LTFU, 4 TO 
LTFU: Missed scheduled 
appointment ≥ 90days 
ART= anti-retroviral treatment, dl = decilitre, CF = clinical failure, FU = follow-up, IF = immunological failure, IVF = immunovirologic failure, IQR = interquartile range, ITT = Intention-to-treat,  LTFU: lost-to-follow-up, 
med = median, ml = millilitre, mo = month/s, OI = opportunistic Infection, re-sup = re-suppressed, pyr = person-years, RIC = retention (retained) in care, SD= standard deviation, TO = transferred out, VF = virologic 
failure, VS = viral suppression VL = viral load, yrs = year/s 
 
 
42 
 
Determinants for outcomes  
In line with the objectives of the protocol, only articles presenting predictors for outcomes 
after first-line treatment failure or after second-line switch, and excluding switch to second-
line or time to switch as an outcome, are presented (Table 6). Measures of association are 
reported if they yielded a statistically significant association (p <0.05).  
11 articles reported on determinants of outcomes after treatment failure (Table 5.A). Most 
studies considered death, LTFU or a combination as the primary outcome(s), two studies 
looked at predictors for survival (30,31), one virologic failure (24), one OIs (30), and two 
studies documented retained and suppressed (VL<80copies/ml) as primary outcome (3,23). 
Most studies looked at the impact of switching to second-line on outcomes, all finding a 
positive effect for those switching after treatment failure. Those who switched were less 
likely to die compared to those not switched after failure (22,26,29–31) less likely to be 
LTFU (21,22,31), to have an OI or a combination of these negative outcomes (21,30) and 
more likely to be retained and suppressed at 18 months (3,23). Rohr et al. found a lower but 
not statistically significant adjusted hazard of death in those who switched between 0 and 
1,5 month after failure versus > 12 months (HRa: 1.21 (95% CI: 0.95-1.54)) (25). Hosseinipour 
et al. found a significant negative effect of clinical failure and low body-mass index on 
mortality and of low CD4-count on mortality or LTFU (28). The study by Murphy et al. found 
that those patients with a mutation were more likely to re-suppress (VL<400 copies/ml) 
(69% vs 37% (p=0.01)) at six months and less likely to be dead (4% vs 16% (p=0.02)) 
compared to patients with wild-type virus, most of whom did not received second-line 
treatment (24). 
19 articles presented determinants for outcomes after switch to second-line ART (Table 
6.B). Most considered virologic outcomes, such as virologic suppression or failure. Some 
articles used a composite end-point for failure, including immunological and clinical failure 
(35), and/or death or LTFU (38) in addition to virologic failure. Many different predictors 
were assessed and found significant, detailed in table 6.B. The most important ones are 
discussed. Seven articles found an association between some indicator of adherence and 
outcomes and two did not (20,34); two articles found positive associations between 
different adherence measures and viral suppression, in univariable (51) and multivariable 
analysis (44). Four articles found that lower adherence was associated with virologic or 
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other definitions of failure (28,35,38,43,46). Five articles found time to switch to be 
significantly associated with outcomes, all indicating benefits of a shorter time between 
failure and switch. Johnston et al. found that viremia for less than a year was associated 
with viral re-suppression in multivariable analysis (34), and Gsponer et al. found a positive 
survival trend with shorter time to switch (31). Others found that a time to switch of over 
one month (45), one and a half months (25), and over six months (46) (> versus faster 
switch) were associated with failure on second-line. SSempijja et al. found that the hazard of 
immunological decrease, virologic increase and an endpoint combining the two were higher 
in patients switched more than one year after failure versus sooner (29).  
Most studies analysed measures of HIV-progression at ART initiation and/or at switch to 
second-line ART as predictor, such as CD4-count, VL or WHO-stage, and findings suggest 
that more advanced disease at start and at switch predicts worse outcomes. While it is hard 
to compare, levels of disease progression in patients in the reviewed papers seemed to be 
advanced at ART initiation, slightly better at failure and again more advanced at switch. At 
initiation, CD4-counts were low, with medians between 62 (IQR, 18-139)(36) and 174 (IQR, 
107-265) cells/mm3 (43). Median CD4 counts at failure were relatively low between 184 
(IQR, 108-279) (27) and 351 (IQR, 182-520) cells/mm3 (3). At switch, median CD4-counts 
were lower again, between 65 (IQR, 22-173) and 212 (IQR, 133-289) cells/mm3(28,45). 
Median/mean log10 VL (copies/ml) ranged between 4.1 (IQR, 3.6 -4.7) to >5 at ART start 
(22,43), 3.9 (IQR, 3.2-4.3) to 4.3 (range, 3.0-5.7) (3,27) at failure, and 4.0 (IQR, 3.6-4.4) to 4.9 
(IQR, 4.5-5.3) (adults) and 5.0 (IQR, 4.6-5.5) (children) at switch (33,45) Of studies reporting 
WHO clinical stage, proportion of advanced clinical stages (III/IV) varied between 40%-86% 
(22,34) at ART-initiation, 32% or 45% (24,29) at failure, and 57%- 89% (21,35) at switch. 
Different multivariable analyses showed that higher CD4 at ART start was positively 
associated with viral re-suppression (44), negatively with failure on second-line (43) and 
LTFU (33), and WHO-stage IV at start was found associated with any type of failure (38). 
Other multivariable models suggested that lower VL and higher CD4 at switch predict 
suppression (34),  patients with lower CD4 at switch or WHO-stage IV at switch are more 
likely to experience death or any failure (35,41), and higher VL at switch predicts attrition 
(47).  
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Two studies found that female sex showed a significant association with VF (>400copies/ml, 
ORa: 2.25 (95% CI: 1.03-4.88) (45), and any type of failure (adjusted for adherence: IRRa: 1.56 
(0.99-2.44)) but in the latter women were less likely to die on second-line (35) (HRa: 0.45 
(95% CI: 0.23- 0.91)). This could mean that among survivors women were less likely to fail, 
but could have similar results to men if death were included among failures. Two studies 
found a significant effect of age in multivariable regression. One study found those with 
older age were less likely to reach viral re-supression (age, per five yrs increase: RRa: 0.87 
(95% CI: 0.79-0.95) (34), a second study found a that attrition was higher in <30 (versus ≥45) 
years of age (HRa: 0.48 (95% CI: 0.27-0.84) (47). 
A positive impact on death, retention in care and clinical disease, as well as viral suppression 
resulting from switching to second-line, and of switching early is found across the included 
studies. Different authors also found that a range of measures of poor adherence predict 
virologic failure and failure overall after switch. A study done on a subset of patients from 
Johnston et al. (34) found that non-adherence (measured as subtherapeutic drug 
concentrations) more than NNRTI-resistance (determined through genotyping), contributed 
to failure after second-line switch (16). Levison et al. also performed genotyping on a group 
of patients on second-line ART, finding that most (67%) patients failing second-line had no 
resistance (17). Murphy also found that second-line treatment yielded better outcomes in 
patients with first-line resistance (24). The 2012 systematic review in LMIC also found that 
poor adherence rather than resistance drove first-line failure in the included studies (5/19 
included studies are also part of this review) (12). First-line adherence predicts second-line 
adherence, and treatment interruptions predict failure (52,53).  
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Table 6: Determinants for outcomes  
A. After treatment failure on first-line ART  
B. After switch to second-line ART   All measures of association are presented with their 95% confidence interval. aAdjusted. b if the reference category is not specified, it is versus “not” 
Table 6.A: After treatment failure on first-line ART  
Reference Main outcome  other predictors assessed Predictors identifiedb Comments  
Gsponer et al. 2012 (31) LTFU  Baseline  Switched: 14(7-26) 51(43-59)/1000 pys (p<0.001)  
 Death   Switched: HRa: 0.25 (0.09-0.72)    
 Survival 5 yrs  Switched 98% vs 91% not switched  Weighted cox models in women <30 yrs 
Hawkins et al. 2017 (21) Death or LTFU ABC vs TDF second-line   Switched : HRa: 0.78 (0.65-0.95)  Restricted to switch after VF (presented) 
 LTFU   Switched : HRa: 0.81 (0.66-0.99) Marginal structure models 
Hosseinipour et al. 2010 (28) Death at 6/12 mo Hb, duration ART, VL value Clinical failure ORa: 3.47 (1.14-10.59) 
BMI <18.5 m2/kg: ORa:  4.43 (1.15-17.12) 
 
 Death or Morbidity at 6 mo   CD4 <50 cells/mm3 ORa: 3.13 (1.05-9.31)  
Keiser et al. 2011 (22) Death  non-failing first-line = 1 
second-line = HRa: 1.60 (0.82-3.14) 
failing first-line = HRa: 3.24 (1.82-5.76) 
Adjust age, sex, nadir CD4 
 LTFU   non-failing first-line = 1 
second-line   = HRa: 2.10 (0.94-4.67) 
failing first-line = HRa: 5.41 (2.70-10.85) 
 
Labhardt et al. 2017  (3) Suppressed & retained at 18 mo  Gender, age, travel time, education, VL 
1, VL2, first line resistance, facility type  
Switched: ORa: 7.17 (1.90-27.04) 
VL <80 copies/ml after EAC: ORa: 5.02 (1.14-22.09) 
Multivariable incl. VL1 result  
Suppressed: VL ≤ 80 copies/ml 
Lejone et al.  (23).     Suppressed & retained at 18 mo  Switched: 38% vs 0% (p= 0.016) Suppressed: VL ≤ 80 copies/ml 
Murphy et al. 2010 (24) Death at 6 mo Gender, resistance, second-line   
regimen, VL failure, WHO-stage failure 
NNRTI-based second-line: 15% vs 2% (p=0.02) 
CD4 ART start<100: 17% vs 2% (p=0.005) 
Univariable analysis, none retained  in multivariable 
analysis  
   Mutation (vs no mutation) : 4% vs 16% (p=0.02) ITT 
 VL ≤400 copies/ml at 6 mo  Mutation (vs no mutation) : 69% vs 37% (p=0.01) ITT 
Petersen et al. 2014 (26) Death first vs second-line, supression prior to 
failure, WHO stage, ART start to failure, 
time since last visit  
Age (+10yrs) OR: 1.80 (1.30–2.51) 
Male: OR: 1.93 (1.09–3.43) 
Nadir CD4: OR: 0.56 (0.36–0.88) 
Most recent CD4: OR:  0.53 (0.37–0.76) 
CD4 decline since failure: 1.17 (1.09–1.27) 
VL at failure: OR: 1.78 (1.22–2.61) 
Seen 90 days prior: 1.82 (1.02–3.27) 
Univariable analysis  
 
 
 
 
Also VL at peak, nadir & most recent are siginificant (not 
presented) 
 Death  ORa:  not switched: 2.1 (1.1-4.2) Adjusted for confounders  
Ramadhani et al. 2016 (30) Survival 
OI 
 
 
 
 
OI or death 
 
Gender, age, duration on ART, site of 
care, adherence 
Switched: 2.3 (1.2-3.9) yrs FU vs 1.0 (0.5-1.4) 
Switched: 38 (5/100pyr) vs 77 (16/100 pyr) 
Prob 6,12 mo: switched 0.03, 0.07 vs 0.12, 0.36 
(p<0.001) 
Switched HRa: 0.4 (0.2-0.6)  
Switched: HRa: 0.2 (0.1-0.2)  
Switched: HRa: 0.4 (0.2-0.7)  
Kaplan Meier curve 
 
 
 
 
Logistic using propensity scoring 
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Rohr et al. 2016  (25) Death   HRa: 1.21 (0.95-1.54) switched >12 mo vs 0-1.5 mo  Marginal structure models, per time of switch (incl. not 
switched), more pronounced in lower CD4 at failure  
SSempijja et al. 2017 (29) Death at 24 mo  Not switched: 12% vs 1% (p=0.009)  
Table 6.B: After switch to second-line ART 
Reference Main outcome  other predictors assessed Predictors identified ( Comments  
Court et al. 2014 (43) VL > 1000 copies/ml Time on second-line, gender, age , VL 
at baseline  
Adherence of 4 months (per 10% increase):  
ORa: 0.73 (1.34- 0.12) 
Square root CD4 ARTtart: ORa: 0.22 (0.35- 0.09) 
Multivariable presented, retained from univariable 
models  
 
De Beaudrap et al. 2013 (20) VL > 1000 copies/ml Adherence level (pill count) /   
Fox et al. 2010 (44) VL <400 copies/ml at 12 mo TB history, BMI at ART start CD4 >200 ART start: HRa: 1.96 (1.21-3.17) 
2 detectable VL before switch: HRa: 1.68 (1.08-2.61) 
Switch for non-compliance, no: HRa: 1.83 (1.14-2.93) 
 
Gsponer et al. 2012 (31) Survival 5 yrs   Time of switch after failure 6, 12, 18: 97%, 96%, 95% Weighted cox models in women <30 yrs 
Hosseinipour et al. 2010 (28) VL >400 copies/ml at 12 mo  Age, gender, time on ART, TB, BMI, Hb, 
missed visits, missed dose, resistance 
CD4 switch <50 cells/mm3 vs >200: OR: 8.6 (2.40-
30.78) 
WHO CF switch: OR: 11.54 (14.5-202.7) 
WHO IF switch: OR: 54.21 (14.5-202.7) 
No active NRTI: OR: 0.17 (0.03-0.94) 
Nr of missed visits: OR: 2.50 (1.35-4.63) 
Univariable analysis  
 
 
 
   Ever missed dose: ORa: 5.70 (1.16-27.93) Multivariable analysis 
Johnston et al. 2012 (34)  VL< 400 copies/ml  VS, first-line ART, non-adherence on 
first-line ART, reason for switch, year of 
switch, new NRTIs in switch regimen, 
reported non-adherence second-line   
ART, gender 
log10 VL switch 4 vs.5 RRa : 1.59 (1.09-2.34)  
Age (+5 yrs) RRa : 0.87 (0.79-0.95) 
Workplace, multivariable  
  Duration of viremia <12 mo: RRa: 1.22 (1.03–1.44) 
Transferred in: RRa: 1.33 (1.11-1.61) 
CD4 switch: 100-199 vs 100: RRa:  1.37 (1.05-1.78) 
Community, multivariable  
Levison et al. 2011 (45) VL >400 copies/ml at 6 mo Age, CD4 count, VL at switch Female: ORa: 2.25 (1.03-4.88) 
Time to switch (+1 mo): ORa: 1.07 (1.01-1.14) 
Multivariable  
Murphy et al. 2012 (42) VL <50 copies/ml at 12 mo  
Adherence ≥ 90% at 12 mo 
Age, gender, adeherence last 6 mo, 
CD4 at second-line  , NRTI 
Adherence  12 mo second-line : OR: 2.5 (1.3-4.8) 
/ 
 
Narainsamy et al. 2017 (46) 2x VL≥ 1000 copies/ml Gender, age, VL at switch, TB history, 
pregnancy, regimen modif, EFV-based 
first-line 
Patients defaulted appointment: RR = 1.9 (1.1-3.2) 
Delay switch>6 mo: RR:1.7 (0.8-3.8), RRa: 1.6 (0.7-
3.5) 
 
Osinusi-Adekanmbi et al. 2014 (40) VL ≥ 1000 copies/ml at 12 mo Gender, age, CD4, genotyping 
sensitivity score, TDF first-line, 
First-line duration ≤24 mo: 13 (34%) vs 19 (54%) 
(p=0.08) 
 
Pujades-Rodríguez et al. 2010  (35) Any failure second-line   
(CF, IF, VF) 
Geography, urbanisation, routine VL, 
gender, use of VL for confirmation, age, 
calender year second-line   start, 
clinical stage at first and second-line   
start, CD4 ART start 
Hospitals vs clinic: IRRa: 1.61 (1.01-2.57) 
CD4 switch vs > 200: 
100-199/mm3: IRRa:  1.59 (0.78- 3.25) 
<50/mm3: IRRa:  3.32 (1.81-6.08) 
Women, adj for adherence: IRRa: 1.56 (0.99-2.44) 
Change 2 NRTI switch: IRRa: 0.64 (0.42-0.96) 
On second-line 6-11 vs >18 mo: IRRa:1.90 (1.19-3.02) 
Adherence <80% vs ≥ 90%: IRRa 3.14 (1.67-5.90) 
Second-line no LPV/r IRRa: 1.61 (0.73- 3.56) 
Sensitivity analysis: definition of immuno-logical 
failure as a CD4 cell count of less than 50/mm3 
instead of less than 100/mm3 gave similar results 
 
 
 
 
   Dissappears after adjustment for adherence 
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 Death  Rural vs urban: HRa: 0.33 (0.12-0.91) 
Women HRa: 0.45 (0.23- 0.91) 
CD4 switch <100/mm3 HRa: 2.83 (1.38-5.80) 
CD4 switch <50/mm3 HRa: 2.74 (1.35-5.58) 
Immunovirologic failure: HRa: 3.17 (1.18-8.50) 
 
 Cohort attrition  Change of second-line regimen HRa: 0.42(0.22-0.80) Sensitivity analysis: + predictors mortality 
Rohr et al. 2016  (25) 2x VL ≥1000 copies/ml  HRa: 2.26 (1.12-4.55) switched 1.5-3 mo vs 0-1.5 mo 
HRa: 2.13 (1.01-4.47) switched 3-6 mo vs 0-1.5 mo  
Marginal structure models, in CD4<100  
Effect dissappear with longer time, survival bias  
Schoffelen et al. 2013 (36) VF  Gender, CD4 switch, time second-line   /   
Shearer et al. 2017  (47) Attrition at 12 mo  Gender, BMI, anemia, TB , regimen 35-39 yrs vs <30: HR: 0.40 (0.23-0.70)  
VL switch ≥ 100,000 vs >5000: HR: 2.19 (1.38-3.46) 
CD4 switch <50 vs ≥ 200: HR: 2.19 (1.38-4.46) 
TB: HR: 2.41 (1.31-4.46) 
Univariable ,  
In multivariable (not presented) VL less significant and 
CD4 not  
 Attrition end of FU  Gender, BMI, anemia, TB , regimen CD4 switch <50 vs ≥ 200: HRa: 1.85 (1.03-3.32) 
Started in 2007-8 (vs 5-6): HRa: 1.64 (1.04-2.60) 
Age ≥45 vs <30: HRa: 0.48 (0.27-0.84) 
Multivariable  
 VL≤400 copies/ml at 12 mo  Gender, BMI, anemia, TB , TDF vs d4T first-line: RRa: 1.22 (1.07-1.39) 
VL switch ≥ 100,000 vs >5000: RRa: 0.79 (0.68-0.92) 
Multivariable  
 VL≤400 copies/ml end of FU  Gender, BMI, anemia, TB , regimen VL switch ≥ 100,000 vs >5000: RR: 0.79 (0.64-0.97) 
CD4 switch <50 vs ≥ 200: RR: 0.62(0.44-0.87) 
Univariable , VL no longer significant in multivariate 
Sigaloff et al. 2012 (38) VL <400 copies/ml, death, LTFU, third-
line 
Any failure (VF, IF, CF, LTFU, death, TO) 
Active regimens, gender, at switch: 
CD4,VL, substitutions, 3-day 
adherence, pills missed,  
Age (yrs): OR 0.94 (0.90-0.98) 
WHO stage IV at start: ORa: 5.25 (1.55-17.7) 
30-day adherence <95%: ORa: 4.08 (1.45-11.5) 
Univariable  logistic regression 
Multivariable logistic regression  
SSempijja et al. 2017 (29)  Imm. Decline 
Vir. Increase 
Composite end-point  
Gender, age, clinic, at initiation: year, 
WHO, CD4, at VF: CD4, VL, year 
Time to switch: ≥25 mo: HR: 4 (1-17) 
13-24 mo HR: 10 (2-53), ≥25 mo: HR: 14 (3-73) 
13-24 mo HR: 5 (1-19), ≥25 mo: HR: 5 (1-17) 
Cox prop. Marginal structure model, ref=0-6 mo  
Univariable , all remained significant in multivariable 
(not presented)  
Tsegaya et al. 2016 (41) Failure: Death, LTFU, CF, IF   Age, Isoniazide, NRTI first-line Weight + 1kg: HRa: 0.92 (0.88-0.95) 
WHO switch IV: HRa: 2.0 (1.1-4.1) cfr I/II 
CD4 switch <100: HRa: 2.0 (1.2-3.5) cfr ≥ 100 
Multivariate, no significant in univariable  
Wilhelmson et al. 2016 (7) LTFU  Age, gender, marital status, running 
water, electricity, WHO stage 
CD4 ART start <100: HR: 1.93 (1.16-3.20) 
Unable to work: HR: 1.97 (1.17-3.33) 
First-line failure confirmed by VL: HR:2.11 (1.16-3,83) 
No education: HR: 1.74 (0.97-3.13) 
Univariable  Cox (p< 0.3) 
 
   CD4 ART START <100: HRa: 2.36 (1.36-4.09) 
First-line failure confirmed by VL: HRa: 2.08 (1.09-
3.98) 
Multivariable Cox  
3TC = lamivudine, ABC = abacavir, ART= anti-retroviral treatment, AZT =zidovudine, BMI = body-mass index,  CF = clinical failure, cop= copies, d4T = stavudine, ddI = didanosine, dl = decilitre, EFV = efavirenz, FTC = 
emtricitabine, FU = follow-up, g = gram, Hb = haemoglobin, HR = hazard ratio, IQR = interquartile range, ITT = intention-to-treat, LPV = lopinavir, LPV/r = lopinavir/ritonavir, LTFU = Lost-to-follow-up, ml = millilitre, 
mo = month/s, NRTI = nucleotide reverse-transcriptase inhibitor, NNRTI = non-nucleotide reverse-transcriptase inhibitor, NVP = nevirapine, OI = opportunistic Infection, OR = Odds ratio, PI = protease-inhibitor, prob 
= probability, RAL = raltegravir, RIC = retention (retained) in care, RR = Risk Ratio, SD= standard deviation, TAM = thymidine-analogue mutation, TB = tuberculosis, TDF = tenofovir, VF = virologic failure, VL = viral 
load.VL1 = first VL after initiation, VL2 = second VL, WHO = World Health Organisation, yrs = years  
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Summary, interpretation and needs for further research  
The 30 included studies were heterogeneous in focus, settings, definitions and reported 
outcomes, limiting comparability. Nevertheless, trends could be seen in the outcomes. 
Failure proportions were comparable to existing evidence, and higher in cohorts with longer 
observation time. Switch rates were moderate to low, and higher when patients were sicker 
(e.g. CF) or when confirmation of failure was performed in some way (i.e. genotyping, 
second elevated VL). Switched to second-line ART versus not switching yielded positive 
outcomes (survival, retention, virologic suppression, CD4) across included articles. The 
timing between failure and switch was overall high, and longer delays predicted failure after 
switch. Overall mortality was low, and higher early after failure. LTFU was moderate to high, 
and likely LTFU masked mortality. Viral re-suppression after second-line switch was 
acceptable, with exceptions from smaller studies. Patients generally had advanced stages of 
disease at initiation on first- and second-line, and both predicted negative treatment 
outcomes. Poor adherence led to adverse outcomes after switch.  
Among all identified studies, none reported on cohorts exclusively managed by nurses. Only 
six studies reported the complete cascade since ART until re-suppression on second-line, 
and only two among them documented first high VL and confirmatory VL as separate steps 
(3,23). We found few cohort studies from West-and-Central Africa, where progress towards 
90-90-90 targets is lower than anywhere else in the world, and HIV-related mortality is high 
(6). Among these, only one describes the VL-cascade until viral re-suppression, but not each 
step, in a long-term cohort including first-line patients (20).  
To inform task-shifting of care for growing groups of patients needing VL monitoring and 
second-line care to nurses, research is needed documenting patient outcomes and their 
determinants, particularly regions with scarcity of skilled staff, such as in West-and Central 
Africa. Those studies should explore each step of the cascade after failure, and determinants 
of outcomes. Such as was done for first-line ART, studies need to establish whether nurse-
led care is non-inferior to doctor-led care (54). The protocol proposed in Section A will, to 
our knowledge, be the first study to document a completely nurse-led cascade until viral 
suppression on second-line, contributing to the necessary evidence to support nurses 
managing treatment failure.  
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Abstract 
Objectives: In a decentralised nurse-led antiretroviral therapy (ART) programme, to assess 
compliance with guidelines for viral load (VL) monitoring and management of treatment 
failure as well as outcomes after a first elevated viral load (VL)≥1000 copies/ml (FEVL), and 
predictors for a “favourable outcome ” defined as retained with supressed VL (<1000 
copies/ml), transferred out or censored at database closure after a suppressed VL.  
Methods: We included patients starting first-line ART from 2007-2017 with a FEVL in three 
facilities in Kinshasa, Democratic Republic of Congo (DRC). We used logistic regression to 
identify predictors of favourable outcomes in adults.  
Results: Of 294 adults with FEVL who did not switch to second-line before confirmatory VL, 
82% had a second VL (VL2) done within 24 months of FEVL at a median (interquartile range 
[IQR]) of 4.0 (3.1-5.6) months) after FEVL. Among patients with VL2 done, 69% had 
VL2≥1000copies/ml, of whom 75% switched to second-line a median of 1.1 (IQR, 0.7-2.0) 
months after VL2. Among 85% of patients not deceased, LTFU or transferred out by 6 
months after second-line switch, 82% had VL<1000 copies/ml. Undergoing VL2 >6 versus ≤3 
months after FEVL (adjusted odds ratio [aOR]: 0.26; 95% Confidence Interval [CI]:0.11-0.67) 
and switching 1-3 versus ≤1 month after VL2≥1000copies/ml (aOR: 0.30; 95%CI:0.10-0.88) 
were independently associated with lower odds of a favourable outcome .  
Conclusion: Nurse-management of the VL-cascade yielded acceptable outcomes in DRC. 
Early detection and fast switch can help improve retention and viral suppression following 
virologic failure. 
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Introduction  
Scarcity of human resources for health hampers provision of quality health care in 
developing countries such as in West- and Central Africa, including for people living with HIV 
(PLHIV) (1). One in three HIV-related deaths happen in West- and Central Africa, where 
antiretroviral therapy (ART) coverage was only 39% and viral suppression 29% in 2016 (2,3). 
A catch-up plan to reach global targets is facing an 81% funding gap, reflecting competing 
priorities in a region ravished by political tension, epidemics and fragile health systems (2). 
Decentralisation and task-shifting of treatment and follow-up of PLHIV on first-line ART to 
nurses and expert patients has contributed to progress toward global targets along the HIV 
90-90-90 “care cascade” (i.e. 90% of patients know their HIV status, 90% of these are on 
treatment, and 90% of ART patients suppress the virus) (4).  
Notwithstanding, treatment failure threatens achievement of care cascade targets (5). Both 
pre-treatment and acquired drug resistance are increasing, with >15% of PLHIV not 
suppressing the virus by 12 months on ART (6–8). Uptake of viral load- (VL) informed care 
has allowed for faster identification of treatment failure and switch to second-line protease-
inhibitor (PI) based regimens, but implementation is challenging (9). Patients identified with 
a first high VL, who might already face barriers to treatment adherence, enter an additional 
elevated “VL-cascade”  including intensive counselling, VL re-testing after 3-6 months, 
switch to second-line if VL remains elevated and return to the original cascade once re-
supressed (10). While the World Health Organisation (WHO) has recommended nurse-led 
care for ‘stable patients’ (i.e. patients with suppressed VL) since 2008 (11), nurse-led 
management of first-line failure and decision making about second-line switch has thus far 
not been recommended. This poses a challenge in settings with limited human resources 
such as the Democratic Republic of Congo (DRC), where decentralised health services are 
exclusively nurse-run (12). Of note, in a referral hospital in DRC 84% of admitted patients 
had advanced HIV disease and only 22% of them were ART-naive, showing the need for 
early detection of virologic failure (VF) and switch (13).  
To our knowledge, outcomes of the complete cascade after an unsuppressed VL (from high 
VL to re-suppression on second-line ART) have not been documented in West-and Central 
Africa, nor for an exclusively nurse-ran programme. Two studies from Lesotho described the 
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VL-cascade for patients in decentralised nurse-led facilities, but second-line switch required 
advice of a central second-line committee (14,15). We aimed to describe the cascade of care 
and outcomes of patients following a first VL≥1000 copies/ml at three nurse-led primary 
health care clinics in Kinshasa, DRC, and to identify predictors for subsequently being 
retained in care and virologically suppressed (<1000 copies/ml). We also examined 
compliance with existing protocols for identification of VF and switch to second-line.  
 
Methods  
Design  
In this retrospective cohort study, we used clinical information that had been routinely 
collected from ART patients in three urban primary health care facilities from 2007 until June 
2018 in Kinshasa, DRC.  
 
Setting   
The health system in DRC is fragile and under constant pressure from disease outbreaks and 
political instability (16). Despite national HIV prevalence of  1.2%, there were nearly 22,000 
HIV-related deaths in 2015 (4). In 2017, estimated ART coverage was 34% (children aged <15 
years) and 58% (adults) (2). The National Programme for the Fight against AIDS and Sexually 
Transmittable Diseases in the DRC is responsible for HIV services and started to treat all 
PLHIV and provide routine annual VL testing in 2016 (17,18). Médecins Sans Frontières 
(MSF) has supported  ART care in the capital Kinshasa since 2002, decentralisation of ART 
services since 2005 and routine VL monitoring since mid-2015 (13,19). The patients in this 
study were enrolled in facilities with exclusive decentralised nurse-led care and treatment 
and clinical mentoring support by MSF.  
Decentralisation 
Decentralisation of HIV care to primary health care facilities was piloted in 2005, and is 
accompanied by training, mentoring and supervision of nurses responsible for 
implementation (Supplementary Table S1). Currently, four to six nurses are trained per facility 
on 12 clinical themes, with a weekly training session and three months of intense mentoring 
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of the trainee per theme. High staff turn-over, and high workload of nurses, not limited to HIV 
care, are challenges restricting continuous mentoring activities. The first community ART 
dispensing points (PODI) in Kinshasa were piloted in 2010. PODI are dispensaries managed by 
patient networks, who provide peer support and ART refills to stable patients between 6-
monthly clinic visits, with good patient retention (19). 
Viral load monitoring 
Before 2015, identification of treatment failure was based on clinical and/or immunological 
criteria confirmed with targeted VL. Routine VL monitoring was implemented mid-2015 in 
MSF-supported facilities. A central VL platform was installed at the referral hospital, with 
sample collection at facility level. The initial routine VL protocol prescribed that all newly 
initiated patients on ART undergo VL testing at six months on ART (or when coming for a 
routine clinical visit if on ART for longer), and yearly thereafter. Patients with a FEVL received 
enhanced adherence counselling (EAC) and were re-tested three months later. If patients had 
a second elevated VL≥1000 copies/ml (SEVL), they were switched to second-line; if the VL was 
<1000 copies/ml they were referred to a facility fast-track circuit or a PODI. Since January 
2017, the protocol was adapted to provide a first VL at three months on ART. Phone-based 
follow-up was implemented to communicate VL results. The major challenges concern 
transport logistics, maintenance of the platform and stockouts of laboratory materials and 
medicines. 
Study population 
We used two cohorts for the analysis. The primary objective was describing patient 
outcomes after FEVL, and a secondary objective was to identify predictors for those 
outcomes (outcome cohort). The other secondary objective was assessing compliance with 
protocols for VL monitoring and switch to second-line in all ART patients (protocol cohort). 
The “outcome cohort” included all patients who started ART between 2007 and 2017, with 
≥1 VL ≥1000 copies/ml >75 days after ART initiation and ≥6 months potential follow-up 
thereafter. We excluded patients on PI-based regimens before FEVL. The analysis of 
predictors of a favourable outcome following FEVL was restricted to adults not censored for 
any reason ≤135 days after FEVL to ensure a reasonable time for clinical interventions to 
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have occurred and impacted outcomes (e.g. 2nd VL, EAC, second-line switch). The “protocol 
cohort” included all patients who started ART on a nonnucleoside reverse transcriptase 
inhibitor (NNRTI)-based regimen between January 2015 and April 2018 after 
implementation of routine VL monitoring, and with >135 days potential follow-up before 
database closure (end June 2018), and thus enough time for a first VL (VL1) measurement to 
have been done.  
Study variables and definitions  
The primary outcome for the “outcome cohort” was a “favourable outcome ” at 12 months 
after FEVL defined as either (i) alive and in care with ≥1 VL <1000 copies/ml by 12 months 
(window of 75-450 days) after FEVL or (ii) transferred out or censored <270 days after FEVL 
with last VL <1000 copies/ml between 75-270 days after FEVL. Patients were considered 
deceased if death was confirmed by a family or community member after telephonic follow-
up. Patients were documented as “transferred out” (TO) if they confirmed in writing that 
they had transferred to a clinic outside the MSF supported clinics or to a PODI. Lost-to-
follow-up (LTFU), was defined as no return for a follow-up visit 90 days after the scheduled 
visit without documented TO or death.  
We defined VL at ART start as a VL result within 30 days after ART initiation, CD4 at ART 
start as a CD4 result within [-180 to +7] days of ART initiation, VL1 as the first VL done >30 
days after ART initiation, and VL2 as the VL measurement after VL1 ≥1000 copies/ml. The 
time windows used were defined as: 1 month; [0-30] days, 2 months; [30-75] days, 3 
months; [76-135] days, 6 months; [136-270] days, 12 months; [271-450] days, 18 months; 
[451-630] days, 24 months; [631-810] days. For instance, “in the 6-month window” means 
between 126-270 days, while by 6 months means ≤270 days. Using these time windows, for 
compliance to protocols, VL1 was considered “on time” if done 31 days to 6 months after 
ART initiation, VL2 was “on time” if done <6 months after a VL1 ≥1000 copies/ml. Switch to 
second-line was considered “on time” within a 2-month window after VL2 ≥1000 copies/ml. 
The cut-off for considering a VL2 “done” was within a 24-month window.  
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Data collection and analysis  
Clinical data were routinely entered by nurses into individual medical records. Data clerks 
entered all paper-based patient records into the national database daily (Tier.Net v1.2.2., 
2011). An epidemiologist conducted monthly file reviews to improve data accuracy and 
where possible, complete missing data. De-identified data were extracted from Tier.Net for 
this analysis. All analyses were performed using Stata/IC 14.1 (StataCorp, Stata Statistical 
Software: College Station, TX). We described characteristics at ART initiation and FEVL using 
medians and interquartile ranges and proportions for continuous and categorical variables 
respectively. We used logistic regression to identify predictors of a favourable outcome at 
12 months after FEVL. The variables facility, age at FEVL, months on ART at FEVL and sex 
were included in the model a priori. Additional variables were added if statistically 
significant (p <0.05) in univariable analysis. If there was collinearity between variables, only 
one was kept in the model. We compared models using Likelihood Ratio tests for nested 
models, model Akaike information criterion and pseudo-R2 for goodness of fit.  
 
Ethical approval  
We were granted approval to conduct the study by the National Health Ethics Committee at 
the Ministry of Health in the DRC and the Human Research Ethics Committee of the 
University of Cape Town. We obtained exemption from ethical review for routinely collected 
data from the Ethics Review Board of MSF. 
 
Results 
Outcomes of the viral load cascade following first elevated viral load 
Among 2550 patients who started ART between 2007 and 2017, 373 (15%) had a FEVL. 316 
patients, including 22 (7%) children, met the inclusion criteria for analysis of outcomes after 
FEVL (Table 1.A).  
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Table 1: Characteristics of patients in three primary health care clinics in Kinshasa, Democratic 
Republic of Congo 
A. with a first elevated viral load (VL) ≥1000 copies/ml after starting first-line ART between 2007 
and 2017 (Outcome cohort)  
B. who started first-line ART after implementation of routine viral load monitoring between 
January 2015 and April 2018 (Protocol cohort)  
 A. Outcome cohort B. Protocol cohort 
Characteristic 
Adults  
(n=294) 
Childrena  
(n=22) 
Adults  
(n=791) 
Children 
(n=54) 
Female (n, %) 217 (74%) 8 (36%) 555 (70%) 23 (43%) 
Median age (yrs) (IQR) at ART initiation 37 (31-44) 7 (3-11) 41 (33-48) 6 (2-12) 
Median age (yrs) (IQR) at FEVL 41 (34-47) 9 (6-13)   
Age (yrs) category at ART initiation, n (%)          [0 - 5]  
                      ]5 - 15]  
                    ]15 - 30]  
                    ]30 - 45]  
                    ]45 - 65]   
                    ]65 - 85]   
 
8 (3%) 
53 (18%) 
167 (57%) 
66 (22%) 
8 (36%) 
14 (64%) 
 
 
128 (16%) 
386 (49%) 
266 (34%) 
11 (1%) 
24 (44%) 
30 (56%) 
Facility (n, %)b                                                                   1 
                                                           2 
                                                           3 
140/961 (15%) 
94/879 (11%) 
60/710 (8%) 
8/961 (1%) 
10/879 (1%) 
4/710 (1%) 
456 (58%) 
200 (25%) 
135 (17%) 
34 (63%) 
9 (17%) 
11 (20%) 
Year ART start(n, %)                                       2007-2010  
                                                       2011-2014 
                      2015-2017  
42 (14%) 
132 (45%) 
120 (41%) 
1 (5%) 
10 (45%) 
11 (50%) 
  
WHO stage at ART initiation (n, %)                             1  
                                                                                           2 
                                                                                           3 
                                                                                           4 
                                                                     Not recorded 
30 (10%) 
72 (24%) 
173 (59%) 
14 (5%) 
5 (2%) 
4 (18%) 
4 (18%) 
10 (45%) 
4 (18%) 
/ 
 
238 (30%) 
86 (11%) 
361 (46%) 
104 (13%) 
2 (0%) 
23 (43%) 
7 (13%) 
20 (37%) 
3 (6%) 
1 (1%) 
Median CD4 (cells/mm3) (IQR) at ART initiation c 153 (73-273)  389 (68-519)  201 (87-360)  418 (298-879) 
Median CD4 (cells/mm3) (IQR) at FEVLd 180 (86-325)  273 (22-486)    
Median log VL (copies/ml) (IQR) at ART initiatione 4.7 (2.4-5.2)  1.6 (1.6-2.3)  2.0 (1.6-2.4)  
Median log FEVL (copies/ml) (IQR)  4.4 (3.8-5.0) 4.4 (3.6-4.8)   
Median time (mo) on ART (IQR) at end of follow-up  46 (28-69) 39 (32-64) 13 (6-20) 13 (4-23) 
Median time (mo) on ART (IQR) at FEVL 28 (12-52) 19 (11-39)   
Regimen at ART initiation (n, %)    NRTI                  AZT 
                                                                                       TDF 
                                                                              d4T/ABC                                                                                           
                                         NNRTI               EFV  
                                                                          NVP        
186 (63%) 
102 (35%) 
6 (2%) 
160 (54%) 
134 (46%) 
20 (91%) 
2 (9%) 
17 (77%) 
5 (23) 
84 (11%) 
697 (88%) 
10 (1%) 
737 (93%)  
54 (7%) 
36 (67%) 
14 (26%) 
4 (7%) 
20 (37%) 
34 (63%) 
ABC = abacavir, ART = antiretroviral treatment, AZT = zidovudine, EFV = efavirenz, ml = milliliter, mm= millimeter, mo = 
month/s, NNRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, NVP = 
nevirapine, IQR = interquartile range, TDF = tenofovir, VL = viral load, FEVL = VL ≥1000 cop/ml minimum 75 days after ART-
start, yrs= years.  
 
a In A: Children are defined as those of age ≤15 years at FEVL. 
b In A: Facility proportions are presented as proportions of all ART patients on ART between 2007 and 2017 in those 
facilities, also for children, who are defined by age at FEVL.  
c In A: n=204 for adults and n=16 for children. In B: n=505 for adults and n= 30 for children 
d In A: n=101 for adults and n=6 for children  
e In A: n=23 for adults and n= 0 for children. In B: n=317 for adults and n=9 for children 
 
 
65 
 
 
 
 
 
 
Figure 1: Viral load cascade and outcomes at 24 months for adults >15 years old at first VL ≥1000 
copies/ml between 2007 and 2017 in three primary health care clinics in Kinshasa, Democratic 
Republic of Congo.  
VL results and second-line switch at 24 months include patients in care and administratively censored.  
FEVL = first elevated VL; first VL ≥ 1000 copies/ml minimum 75 days after ART-start, IQR = interquartile range, mo = 
months, LTFU = lost-to follow-up, TO = transferred out, VL = viral load, VL2 = first VL after FEVL, SEVL = second elevated VL 
 
Adults  
Among adults who had not reached administrative censoring, 204 (74%), 146 (61%), 99 
(48%), and 35 (24%) respectively were alive and in care by 6, 12, 18 and 24 months after 
FEVL (Figure 2, Supplementary table S2). Overall, by the same time points, 9 (3%), 12 (4%), 
16 (5%) and 16 (5%) of adults had been transferred out, and 47 (16%), 62 (21%), 71 (24%), 
and 73 (25%) had been LTFU. 16 (5%) had died by 6 months, 21 (7%) by 12 months.  
 
FEVL: VL≥ 1000 
copies/ml 
294
VL2 done  
242 (82%)
Median days FEVL to VL2  (IQR) : 119 (93-169) 
SEVL: VL2  1000 
copies/ml
167 (69%)
Ever switched to 
second-line ART
125 (75%)
Median days SEVL to switch (IQR) : 34 (21-60)  
21 (17%) LTFU 
4 (3%) died 
4 (3%) TO 
79 (63%) VL<1000
17 (14%) VL  1000
99% (95) second-
line at 24 mo 
Never switched 
42 (25%)
13 (31%) LTFU 
5 (12%) died 
3 (7%) TO
9 (21%) VL<1000
12 (29%) VL  1000
No second-line at 
24 mo 
VL2 < 1000 
copies/ml 
75 (31%) 
16 (21%) LTFU
3 (4%) died 
56 (75%) VL<1000
8 (14%) second-
line at 24 mo 
Switched to second-
line before VL2  
10 (3%)
2 (20%) TO 
1 (10%) LTFU 
3 (30%) VL<1000
4 (40%) VL  1000
7 (100%) second-
line at 24 mo 
no VL2 by 24 mo 
42 (14%)
7 (17%) TO 
9 (21%) died
22 (52%) LTFU
4 (10%) no VL
No second-line 
at 24 mo 
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Table 2: Outcomes per time-window for adults who ever switched to second-line ART after two 
elevated viral loads (≥1000 copies/ml) between 2007 and 2017 in three primary health care clinics 
in Kinshasa, Democratic Republic of Congo.  
Time after FEVL By 6-months By 12-months  By 18-months  By 24-months  
In care or administratively censored (n, % of 125) 122 (98%) 108 (86%) 97 (78%) 96 (77%) 
VL2 done (n, %)  111 (91%) 107 (99%) 96 (99%) 96 (100%) 
Switched to second-line ART (n, %) 100 (82%) 106 (98%) 96 (99%) 95 (99%) 
Ever re-suppressed (n, %) 34 (28%) 73 (68%) 77 (79%) 79 (82%) 
ART = Antiretroviral treatment, FEVL = first VL≥1000 copies/ml >75 days after ART-start. VL2 = VL after FEVL. 
 
252 (86%) of 294 adult patients either had VL2 done (n=242) or were switched to second-
line after FEVL without a confirmatory VL (VL2) (n=10) (Figure 1). Cumulatively, by 6, 12, and 
24 months, 231 (79%), 247 (84%), and 252 (86%) of the total 294 adults had a VL2 result 
(Figure 2). Of the 242 patients with a VL2 result, 167 (69%) had a second elevated VL ≥1000 
copies/ml (SEVL). Among all patient with a SEVL irrespective of final outcome (death, TO, 
LTFU), 120 (77%), 141 (82%), 142 (83%), and 144 (83%) had ever been switched to second-
line ART by 6, 12, 18 and 24 months. Table 2 presents outcomes of 125 patients with SEVL 
who switched to second-line ART over SEVL (one switched >24 months after FEVL).  
Outcomes after switch  
Of patients on second-line ART who were not administratively censored, 105 (85%) and 74 
(72%) were in care by 6 and 12 months after switch, 99 (94%) and 72 (97%) had ≥1 VL result, 
of whom 86 (87%) and 63 (88%) had VL<1000 copies/ml. Overall, by 6 and 12 months, 2 
(1%) and 4 (3%) were transferred out, 12 (8%) and 21 (15%) were LTFU, and 4 (3%) died by 6 
months after switch. 
Children  
Of 22 included children, 21 (96%) had a VL2 result with a median of 133 (IQR, 112-189) days 
between FEVL and VL2 (Supplementary figure S3).  16/22 (76%) had a SEVL, 15 (94%) of 
whom were switched to second-line at a median of 30 (IQR, 19-66) days after SEVL. Of those 
children not administratively censored by 6 and 12 months, 17 (89%) and 12 (80%) were 
alive in care. Overall, 3 (14%) were LTFU by 12 months, none died. Of those in care 6 and 12 
months after switch to second-line, 8 (80%) and 7 (78%) had a VL≤ 1000 copies/ml.   
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Figure 2: Kaplan-Meier estimates of proportions of adult patients with first elevated VL ≥1000 
copies/ml between 2007 and 2017 in three primary health care clinics in Kinshasa, Democratic 
Republic of Congo 
A. Of having a VL2 done after FEVL among those with FEVL (upper left panel)
B. Of switching to second-line ART after SEVL among those with SEVL (upper right panel)
C. Of death or LTFU after SEVL, by switched or not switched to second-line ART among those
with SEVL (lower left panel)
FEVL = first elevated VL; first VL ≥ 1000 copies/ml minimum 75 days after ART-start, IQR = interquartile range, mo = 
months, LTFU = lost-to follow-up, VL = viral load, VL2 = first VL after FEVL, SEVL = second elevated VL; VL2≥ 1000 copies/ml 
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Table 3: Predictors for a favourable outcome at 12 months after a first VL ≥1000 copies/ml in three primary health care clinics in Kinshasa, Democratic 
Republic of Congo. 
 A favourable outcome is not being dead, LTFU or transferred out or administratively censored with a last VL ≥1000 copies/ml. Predictors with a significant effect are presented in bold.  
ART= antiretroviral treatment, CI = confidence Interval, FEVL = first VL 75 days after ART start≥ 1000 copies/ml, IQR = interquartile range, mo = month/s, aOR =Adjusted Odds ratio, VL = viral 
load, WHO = World Health Organization, yrs = years.  
a restricted to 240 patients with a second VL  
b restricted to 120 patients switched to second-line maximum ≤270 days after FEVL
Characteristics 
N, column % or 
median (IQR) 
All patients (n=250) Patients with second VL (n=240) Patients on second-line (n=120) 
aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value 
Male sex 56 (26%) 0.59 (0.32-1.08) 0.087 0.60 (0.32-1.15) 0.123 0.62 (0.21-1.82) 0.379 
Median (IQR) age (yrs) at FEVL 41 (33-47) 1.02 (0.99-1.04) 0.169 1.02 (0.99-1.05) 0.149 1.06 (1.01-1.11) 0.013 
Facility        1 113 (45%) 1 1 1 
Facility        2 85 (34%) 1.44 (0.78-2.68) 0.242 1.22 (0.63-2.35) 0.556 1.88 (0.61-5.79) 0.269 
Facility        3 52 (21%) 1.23 (0.61-2.47) 0.560 0.84 (0.40-1.78) 0.655 0.40 (0.13-1.27) 0.120 
WHO stage at ART initiation:       1 24 (10%) 1 1 1 
WHO stage at ART initiation:    2 63 (25%) 0.24 (0.07-0.80) 0.021 0.29 (0.08-1.00) 0.051 0.24 (0.03-1.85) 0.171 
WHO stage at ART initiation:    3/4 160 (64%) 0.27 (0.08-0.84) 0.024 0.36 (0.11-1.15) 0.087 0.69 (0.10-4.57) 0.237 
WHO stage at ART initiation:    not recorded 3 (1%) 0.08 (0.01-1.21) 0.068 0.09 (0.01-1.35) 0.081 omitted 
Log FEVL  4.3 (3.7-4.9) 0.77 (0.56-1.06) 0.104 0.69 (0.49-0.98) 0.037 0.83 (0.51-1.73) 0.829 
Time (mo) on ART at FEVL   ≤ 24 mo 108 (43%) 1 1 1 
 24 - 48  mo 69 (28%) 0.99 (0.52-1.91) 0.979 0.92 (0.46-1.82) 0.809 1.48 (0.46-4.72) 0.510 
 > 48  mo 73 (29%) 0.87 (0.46-1.67) 0.684 0.86 (0.43-1.70) 0.660 1.75 (0.60-5.10) 0.304 
Time (mo) between FEVL and second VLa:    ≤ 3 mo 38 (16%) 1 1 
      3 - 6  mo 151 (63%) 0.76 (0.34-1.68) 0.500 0.70 (0.19-2.56) 0.588 
> 6  mo 51 (21%) 0.26 (0.11-0.67) 0.005 0.30 (0.04-2.13) 0.232 
Time (mo) between second VL and switchb: ≤ 1 mo  57 (48%) 1 
      1 - 3   mo  43 (36%) 0.30 (0.10-0.88) 0.029 
> 3    mo 10 (8%) 0.32 (0.05-1.73) 0.186 
  switch before second VL 10 (8%) 0.20 (0.04-1.09) 0.123 
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Table 4: Compliance to guidelines for identification of virologic failure and switch to second-line 
ART in patients started on ART between January 2015 and April 2018 in three primary health 
facilities in Kinshasa, Democratic Republic of Congo. 
The timing of the steps in the protocol for virologic failure identification and switch to second-line ART are presented 
cumulatively as performed by the end of the time window. Results that meet the timing or switching criteria are presented 
in bold. 
VL1 done  VL2 done  Switch to second-line ART  
618/845 (73%) a 67/97 (69%) b 27/41 (66%) c 
Timing VL1 after ART-start Timing VL2 after VL1  Timing switch after VL2 
NRTI before and after 
switch 
266 (43%)   3 mo 45 (67%)   3 mo 2 (7%)  Before VL2 2 (7%) AZT - ABC 
521 (84%)   6 mo 64 (96%)   6 mo 14 (52%) 1 mo 5 (19%) AZT - TDF 
593 (96%)   12 mo 67 (100%)  12 mo 20 (81%) 2 mo 3 (11%) TDF - ABC 
618 (100%) > 12 mo 26 (96%) 3 mo 14 (52%) TDF - AZT  
27 (100%)  6 mo 3 (11%)  TDF - TDF 
ABC = abacavir, ART = antiretroviral treatment, AZT = zidovudine, EFV = efavirenz, ml = milliliter, mo = month/s, NRTI = 
nucleoside reverse transcriptase inhibitor, NVP = nevirapine, TDF = tenofovir, VL = viral load, VL1 = first VL minimum 30 
days after ART-start, VL2 = first VL after VL1 
a excluding VL less than 30 days after ART start 
b among those with VL1 ≥1000 copies/ml 
c among those with VL2 ≥1000 copies/ml 
Analysis of predictors for favourable treatment outcomes 
250 adult patients with a FEVL and ≥135 days subsequent follow-up were included in the 
analysis of outcome predictors (Table 1.B). 142 (57%) had a favourable outcome at 12 
months. Only WHO stage was associated with a favourable outcome: Stage 2 (vs 1) 
(aOR):0.24 (95% CI: 0.07-0.80)) and Stage 3/4 (vs 1) (aOR):0.27 (95% CI: 0.08-0.84) (Table 3). 
In 240 patients with a VL after FEVL, 142 (59%) had a favourable outcome at 12 months. >6 
months between FEVL and VL2 (vs ≤3) (aOR: 0.26 (95% CI: 0.11-0.67)) and log10 FEVL (aOR:
0.69 per unit increase (95% CI: 0.49-0.98)) were independently associated with reduced 
likelihood of a favourable outcome at 12 months after FEVL. In 120 patients who switched 
to second-line <270 days after FEVL, 78 (65%) had a favourable outcome at 12 months. 
Switching 1-3 months (vs ≤1 month) after FEVL reduced (aOR: 0.30 (95% CI: 0.10-0.88) and a 
higher age at FEVL ((aOR: 1.06 per year (95% CI: 1.01-1.11)) slightly increased the odds of a 
favourable outcome.  
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Compliance to protocols for identification of virologic failure and switch to 
second-line ART 
 Of 845 patients in the “protocol cohort” (Table 1.B), 618 (73%) had a VL1 (507 (84%) on 
time) (Table 4). Out of 97 patients with a VL1 ≥1000 copies/ml, 67 (69%) had a VL2 done (64 
(96%) on time). 27 (66%) of patients with a VL2 ≥1000 copies/ml were switched to second-
line (20 (81%) switched on time; 24 (89%) changed NRTI appropriately).   
 
Discussion 
Our study showed acceptable compliance with the VL-cascade in a nurse-ran programme in 
Kinshasa (82% of those with VL1≥1000 copies/ml had VL2 done before switch, 91% within 6 
months, 75% of those with SEVL were switched to second-line, 91% within 3 months), and 
those who switched to second-line had good outcomes. After routine VL implementation, 
coverage was lower but timing was well adhered to (73% had a VL1 done, 84% within 6 
months after initiation, 69% of those with a VL1≥1000 copies/ml had VL2 done, 96% within 
6 months, 66% of those with a SEVL switched to second-line, 96% within 3 months). Nurses 
switched patients with confirmed elevated viral load quickly, which was associated with 
better outcomes; patients switching within a month of SEVL being significantly more likely 
to be retained and virologically suppressed by 12 months after SEVL.  
Fifteen per cent of patients started on ART had a first high VL, in line with published estimates 
of first-line failure in LMIC (20). Similar to our results were findings from Lesotho, where 84% 
of adults and 93% of children with a FEVL had a second VL result (14,15). Two large studies in 
South Africa found shorter (2-3 months) time from FEVL to confirmatory VL than ours, others 
reported longer delays (21–25). Proportions switched among patients with SEVL were similar 
or better in comparison to studies using the same switch criteria (14,21,24). Higher 
proportions switched were reported in a study using genotyping as confirmation (76%) and 
targeted VL testing (93%) (26,27). Confirmation of the test result, with adherence support 
between tests, could give health-care workers more confidence to switch without fear of 
“wasting” regimens on patients with poor adherence. Time from failure to switch in the 
“outcome cohort” was particularly short, with recent studies reporting between 2-8 months 
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in South Africa and up to 15 months in Tanzanian clinics (24,28,29). Similar to studies which 
were doctor-led, high proportions of adults (88%) and children (78%) re-suppressed after 
switch (30–33). One study with genotyping-informed regimen-switch reported 93% (26). In 
comparison, in the nurse-led study in Lesotho, only 32% of adults and 38% of children re-
supressed (14,15). Overall, VL-cascade results were less positive in the “protocol cohort”, but 
comparable to doctor-led studies, and timelines and correct NRTI-change were mostly 
respected. Because VL was targeted until 2015, a VL was more likely to be done in patients 
who already had advanced disease which could have urged nurses to switch faster if VL was 
found to be high (24). Notably, the “outcome cohort” had lower CD4 at initiation and more 
advanced WHO clinical stage than the “protocol cohort”.  
Mortality was low with higher early mortality, which has been documented elsewhere to be 
related to advanced HIV at ART initiation (27,34,35). LTFU was high, especially early, with 
16% lost 6 months and 25% two years after FEVL respectively, and 15% LTFU one year after 
switch. Studies report LTFU after failure ranging from 9% at 12 to 21% at 18-19 months 
(14,23,26), and after switch from 4-17% at 6 and 8-14% at 12-15 months respectively 
(30,31,36–38).  One DRC study found retention on first-line ART of 65% and 57% at 1 and 2 
years (39), and patients who have failed first-line are likely to have worse retention (35). As 
mortality is low and LTFU is high and early, LTFU is may mask (early) mortality (35).  
We did not find an independent association between switch and a favourable outcome , 
despite extensive reporting of this in the literature (14,15,29,41). As we include all patients 
who had a FEVL in the analysis, the lack of association could be due to some patients re-
suppressing without switch. Also, we had too few patients and outcomes to use causal 
analysis methods, and there is likely confounding by indication whereby sicker patients are 
more likely to be switched, which could attenuate the effect of switch on outcomes. Older 
patients had a slightly higher chance of a favourable outcome in the second-line group. 
Older patients also had a lower hazard of attrition (Age ≥45 vs <30: adjusted hazard ratio: 
0.48 (95% CI: 0.27-0.84)) in a South African study (28). Younger patients could be less likely 
to adhere well to second-line ART due to developmental and lifestyle factors associated 
with youth.   
Longer time to confirmatory VL in those with VL2 (>6 vs ≤3 months) and between VL2 and 
switch (1-3 months vs <1 month) in those switched predicted negative outcomes. Although 
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we found no significant negative association with >3 months versus <1 month between SEVL 
and switch and being retained and suppressed, the direction of effect was similar to a 1-3 
months vs <1-month delay and the number of patients switching after 3 months was very 
small. Delays in switch have been extensively shown to predict adverse virologic outcomes 
(25,30,36,38). Time compliance for confirmatory VL testing and switch is thus essential for 
good health outcomes, and it is very reassuring that nurses in this routine programme in 
Kinshasa adhered to time guidelines.  
Reaching all patients for initial VL after routine implementation was challenging, and likely 
reflects troubleshooting at implementation, such as maintenance of the VL platform, 
reagent supply gaps, sample transport, return of results and limited initial experience of 
nurses. Funding gaps and supply challenges have been reported to disrupt HIV-services in 
the DRC, including VL testing (12,42). Electoral tensions also led to disruptions in health 
services in Kinshasa in recent years, which is not uncommon in the DRC (16). A systematic 
review showed inconsistent results from decentralised ART monitoring in LMIC, highlighting 
the need for point-of-care VL testing (43).  
This is the first study of an exclusively nurse-managed VL-cascade including switch, and the 
first study in West-and Central Africa to report different steps in the VL-cascade, necessary 
to address bottlenecks to reaching universal targets to end HIV (35,43). Data from routine 
conditions represent the reality for most patients in national programmes, which cannot be 
derived from controlled conditions. Nevertheless, our study has several limitations. The 
retrospective design did not allow measurement of other factors that could have helped to 
explain the results, and missing data could not be retrieved. For instance, we could not 
report on the numbers of EAC sessions held, a and did not have data on adherence or 
genotyping to better understand reasons for failure. Replacement of CD4-monitoring with 
VL-monitoring after VL-scale-up led to CD4-counts not being done for all patients at 
initiation nor at FEVL. The fact that neither were significant as outcome predictors could be 
linked to the incompleteness of data. The retrospective design also limits accuracy of data, 
leading to potential bias. For instance, missing VL results could reflect a VL not done, a 
missing VL result in the patient file, or an encoding error, not always identifiable through file 
review. A first VL 31 days after ART-start could be too early for the second VL to be a 
relevant measurement for viral re-suppression, but no patient had a first VL done between 
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31 and 75 days after ART-start. Due to lack of a control group we could not establish non-
inferiority between nurse-and doctor led care. The high LTFU and high numbers of patients 
administratively censored throughout the follow up lead to selection bias. The high LTFU 
could have many reasons. Patients present with advanced disease in Kinshasa, and 
advanced disease predicts LTFU which masks mortality (13). The highly stigmatised status 
HIV in the DRC could lead patients to drop in and out of different clinics, and re-present 
non-ART-naive and severely ill (20). Other patient-level barriers to retention can be cost, 
time, transportation (44). Although officially HIV-care provided free-of-charge, laboratory 
tests and medicines other than antiretrovirals are often subject to user fees (45). Health 
system factors such as high workload of poorly remunerated nurses, and regular shortages 
of medicines and lab supplies, all Kinshasa reality, contribute to patients’ disengagement 
with care (42,44). Selection bias may explain part of the association between delays 
between VL-cascade steps and outcomes, as those more adherent to clinic visits and 
returning faster, are more likely to have had a second VL and switch done earlier, hence 
more likely to re-suppress. Finally, the support from MSF, even if limited to logistics support 
and mentoring, could have helped to improve results, such as timing between SEVL and 
switch.  
Growing numbers of patients with VF in need of second-line ART urge for task-shifting of 
management of the VL-cascade. Our study shows that a nurse-led decentralised programme 
in a challenging context can yield comparable results to doctor-led studies in similar or more 
developed contexts. Appropriate logistical support and continued quality training and 
mentoring for nursing staff, accompanied by adequate funding, are conditions to successful 
implementation. Task-shifting could allow more time for doctors to deal with complex cases, 
for example related to PI-induced drug toxicities or drug-drug interactions. While our study 
focuses on nurse-led care, task-shifting from doctors can occur to other cadres such as 
clinical officers, depending on context-specific availability (43). As pre-treatment drug 
resistance is increasing, many countries consider dolutegravir-based regimens for ART-naive 
and ART-non-naive patients. Dolutegravir has a high genetic barrier, and evidence suggests 
it is superior and it better tolerable than NRTI and PI-based regimens (46). Appropriate 
monitoring of long-term outcomes and resistance, with the human resources available, will 
be essential to preserve this drug for future generations. More research, including studies 
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comparing nurse- to doctor-led care, is needed to show feasibility and results of nurse-led 
programmes in rural areas and other contexts. Nurse-led management of the VL-cascade 
contributes to reach global targets in the HIV-response and should be widely implemented. 
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Supplementary tables and figures  
Supplementary Table S1: Chronology of decentralisation process and important protocol changes in 
an anti-retroviral treatment programme supported by Médecins Sans Frontières, Kinshasa, 
Democratic Republic of Congo. 
3TC = lamivudine, ART = Antiretroviral Treatment, AZT = zidovudine, CHK = Centre Hospitalier Kabinda, EFV = efavirenz , NVP 
= nevirapine, TDF = tenofovir. VL = viral load 
Timing MSF supported programme Kinshasa National protocols, policy changes 
2002 HIV-testing and treatment of opportunistic infections at ambulatory treatment 
centre Kabinda 
2003 Start of ART at centre Kabinda 
2005 Decentralisation of ART patients to four health centres, integration of ART care in 
nurse-led primary health care 
Hand-over to Ministry of health of 3000 patients from centre Kabinda (1400 on ART) 
2008 Start hospitalisation unit Centre Hospitalier Kabinda (CHK) with 24 beds 
2010 Start of three ART dispensing points in the community (PODI) (19) 
2012 CHK becomes referral centre, all stable patients are decentralised 
2013 Further decentralisation towards 10 health centres in the health zone of Masina I 
2014 Start community ART groups, fast-track refills 
2015 Increased capacity for CHK to 41 beds 
Start of viral load platform at CHK 
First VL done at 6 months on ART  
Rationalisation process separating support to clinics 
providing ART per donor   
First-line becomes TDF/3TC/EFV instead of 
AZT/3TC/NVP, leading to stock-outs of former (42) 
2016 Start test & treat and clinical mentoring activities 
Hand-over 2 PODIs to partners 
Acceleration plan (17,18): Test and treat and routine 
viral load testing with first VL after 6 months on ART. 
VL replaces CD4 for monitoring of ART patients.  
2017 Protocol change: first VL after 3 months on ART 
2018 Clinical mentoring in CHK, two general hospitals and health centres (including 
studied facilities) 
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Supplementary Table S2:  Cumulative outcomes per time-window of patients after a first viral load ≥1000 copies/mL between 2007 and 2017 in three 
primary health care clinics in Kinshasa, Democratic Republic of Congo.  
A. All patients. Stratified per adults and children.
B. Patients with two consecutive VL results ≥ 1000 copies/ml (SEVL) after ART start who were switched to second-line. Stratified per adults and children.
C. All adult patients. Stratified per ever switched to second-line and never switched to second-line 
A. All patients End of 6-months window End of 12-months window End of 18-months window End of 24-months window 
Status Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done Switched/ Total 
Alive in care  69% (204) 24% (92/177) 54% (110/204) 50% (146) 76% (106/140) 68% (99/146) 34% (99) 88% (84/96) 69% (68/99) 12% (35) 91% (31/34) 63% (22/35) 
Admin. censored 6% (18) 59% (10/17) 33% (6/18) 18% (53)  72% (36/50) 42% (22/53) 30% (87) 76% (64/84) 47% (41/87) 51% (149) 81% (118/146) 59% (88/149) 
Transferred out 3% (9) 0% (0/3) 0% (0/9) 4% (12) 20% (1/5) 17% (2/12) 5% (16) 33% (3/9) 38% (6/16) 5% (16) 33% (3/9) 38% (6/16) 
Dead 5% (16) 29% (2/7) 6% (1/16) 7% (21) 42% (5/12) 19% (4/21) 7% (21) 42% (5/12) 19% (4/21) 7% (21) 42% (5/12) 19% (4/21) 
LTFU 16% (47) 71% (12/27) 6% (3/47) 21% (62) 53% (21/40) 23% (14/62) 24% (71) 59% (29/49) 32% (23/71) 25% (73) 61% (31/51) 33% (24/73) 
Total adults 100% (294)  50% (116/231) 41% (120/294) 100% (294) 68% (169/247) 48% (141/294) 100% (294) 74% (185/250) 48% (142/294) 294 75% (188/252) 49% (144/294) 
Alive in care  77% (17) 21% (3/14) 35% (6/17) 55% (12) 73% (8/11) 83% (10/12) 36% (8) 71% (5/7) 88% (7/8) 14% (3) 100% (3/3) 67% (2/3) 
Alive, end of follow-up 14% (3) 33% (1/3) 67% (2/3) 32% (7) 33% (2/6) 43% (3/7) 50% (11) 50% (5/10) 64% (7/11) 64% (14) 62% (8/13) 71% (10/14) 
Transferred out  5% (1) 100% (1/1) 100% (1/1) 
Dead 
LTFU 9% (2) 100% (1/1) 0% (0/2) 14% (3) 67% (2/3) 33% (1/3) 14% (3) 67% (2/3) 33% (1/3) 18% (4) 50% (2/4) 50% (2/4) 
Total children  100% (22) 28% (5/18) 36% (8/22) 100% (22) 60% (12/20) 64% (14/22) 100 % (22) 60% (12/20) 68% (15/22) 100% (22) 67% (14/21) 68% (15/22) 
B. Patients who
switched after
SEVL
Status 
End of 6-months window End of 12-months window End of 18-months window End of 24-months window 
Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done Switched/ Total 
Alive in care  94% (117) 32% (34/106) 81% (95/117) 74% (93)  71% (65/92) 98% (91/93) 53% (66) 85% (55/65) 98% (65/66) 17% (21)  90% (19/21) 95% (20/21) 
Alive, end of follow-up 4% (5) 0% (0/5) 100% (5/5) 12% (15)  53% (8/15) 100% (15/15) 25% (31) 71% (22/31) 100% (31/31) 60% (75) 80% (60/75) 100% (75/75) 
Transferred out  1% (1) 0% (0/1) 100% (1/1) 3% (4) 50% (2/4) 100% (4/4) 3% (4) 50% (2/4) 100% (4/4) 
Dead 1% (1) 0% (0/1) 100% (1/1) 3% (4) 50% (2/4) 100% (4/4) 3% (4) 50% (2/4) 100% (4/4) 3% (4) 50% (2/4) 100% (4/4) 
LTFU 2% (2) 0% (0/2) 100% (2/2) 5% (6) 50% (6/12) 100% (12/12) 16% (20) 65% (13/20) 100% (20/20) 17% (21) 67% (14/21) 100% (21/21) 
Total adults  100% (125) 30% (34/114) 82% (103/125) 100% (125) 65% (81/124) 98% (123/125) 100% (125) 76% (94/124) 99% (124/125) 100% (125) 76% (97/125) 99% (124/125) 
Alive in care  87% (13) 15% (2/13) 85% (11/13) 73% (11) 73% (8/11) 91% (10/11) 47% (7) 71% (5/7) 100% (7/7) 13% (2) 100% (2/2) 100% (2/2) 
Alive, end of follow-up 13% (2) 0% (0/2) 100% (2/2) 20% (3) 0% (0/3) 100% (3/3) 47% (7) 43% (3/7) 00% (7/7) 67% (10) 60% (6/10) 100% (10/10) 
Transferred out  7% (1) 100% (1/1) 100% (1/1) 
Dead 
LTFU 7% (1) 0% (0/1) 100% (1/1) 7% (1) 0% (0/1) 100% (1/1) 13% (2) 0% (0/2) 100% (2/2) 
Total children  100% (15) 13% (2/15) 87% (13/15) 100% (15) 53% (8/15) 93% (14/15) 100% (15) 53% (8/15) 100% (15/15) 100% (15) 60% (9/15) 100% (15/15) 
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Admin = administratively. ART = antiretroviral treatment. Re-sup = ever re-suppressed, or at least one VL < 1000 copies/ml after the VL1 ≥ 1000 copies/ml. SEVL = second elevated VL, VL = 
viral load 
C. All Adult
patients
End of 6-months window End of 12-months window End of 18-months window End of 24-months window 
Status Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done 
Switched/ 
Total Total 
Re-sup/ 
VL done 
Switched/ 
 Total 
Alive in care  93% (135) 37% (46/123)   81% (110/135) 71% (103) 69% (70/101) 96% (99/103) 49% (71) 83% (58/70) 96% (68/71) 16% (23) 96% (22/23) 96% (22/23) 
Alive, end of follow-up 4% (6) 17% (1/6) 100% (6/6) 15% (22) 64% (14/22) 100% (22/22) 28% (41) 73% (30/41) 100% (41/41) 61% (88) 78% (69/88) 100% (88/88) 
Transferred out  1% (2) 50% (1/2) 100% (2/2) 4% (6) 50% (3/6) 100% (6/6) 4% (6) 50% (3/6) 100% (6/6) 
Dead 1% (1) 0% (0/1) 100% (1/1) 3% (4) 50% (2/4) 100% (4/4) 3% (4) 50% (2/4) 100% (4/4) 3% (4) 50% (2/4) 100% (4/4) 
LTFU 2% (3) 0% (0/3) 100% (3/3) 10% (14) 50% (7/14) 100% (14/14) 16% (23) 65% (15/23) 100% (23/23) 17% (24) 67% (16/24) 100% (24/24) 
Total ever second-line 100% (145) 35% (47/133) 83% (120/145) 100% (145) 66% (94/143) 97% (141/145) 100% (145) 75% (108/144) 98% (142/145) 100% (145) 77% (111/145) 99% (144/145) 
Alive in care  46% (69) 85% (46/54) 29% (43) 92% (36/39) 19% (28) 100% (26/26) 8% (12) 91% (10/11) 
Alive, end of follow-up 8% (12) 82% (9/11) 21% (31) 79% (22/28) 31% (46) 79% (34/43) 41% (61) 85% (49/58) 
Transferred out  6% (9) 0% (0/3) 7% (10) 0% (0/3) 7% (10) 0% (0/3) 7% (10) 0% (0/3) 
Dead 10% (15) 33% (2/6) 11% (17) 38% (3/8) 11% (17) 38% (3/8) 11% (17) 38% (3/8) 
LTFU 30% (44) 50% (12/24) 32% (48) 54% (14/26) 32% (48) 54% (14/26) 33% (49) 56% (15/27) 
Total never second-line 100% (149) 70% (69/98) 100% (149) 72% (75/104) 100% (149) 73% (77/106) 100% (149) 72% (77/107) 
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Supplementary Figure S3: Viral load cascade and outcomes at 24 months for children <15 years old 
at first VL ≥1000 copies/ml between 2007 and 2017 in three primary health care clinics in Kinshasa, 
Democratic Republic of Congo.  
VL results and second-line switch at 24 months include patients retained in care and administratively censored.  
ART = anti-retroviral treatment, FEVL = first elevated VL; first VL ≥ 1000 cop/ml minimum 75 days after ART-start, IQR = 
interquartile range, mo = months, LTFU = lost-to follow-up, TO = transferred out, VL = viral load, VL2 = first VL after FEVL. 
SEVL = VL after FEVL ≥1000 copies/ml.  
FEVL: VL 1000 
copies/ml
22
VL2 done
21 (96%)
Median days FEVL to VL2  (IQR) : 133 (112-189) 
SEVL: VL2  1000 
copies/ml
16 (76%)
Switched to second-
line ART
15 (94%)
Median days SEVL to switch (IQR) : 30 (19-66) 
2 (13%) LTFU 
1 (7%) TO
8 (53%) VL <1000
4 (27%) VL  1000
12 (100%) second-
line at 24 mo 
Never switched 
1 (6%)
1 (100%) VL  1000
No second-line at 
24 mo 
VL 2 < 1000 
copies/ml 
5 (24%)
2 (40%) LTFU
3 (60%) VL< 1000 
No 2nd-line
No second-line at 
24 mo 
No VL 2 by 24 mo 
1 (1%)
1 (100%) no VL
no 2nd-line 
no second-line at 
24 mo 
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Supplementary Table S4: Univariable analysis of predictors for a favourable outcome at 12 months after a first VL ≥1000 copies/ml in three primary 
health care clinics in Kinshasa, Democratic Republic of Congo.  
A favourable outcome is not being dead, LTFU or transferred out or administratively censored with a last VL ≥1000 copies/ml. Predictors with a significant effect are presented in bold. 
Characteristics N, column % or median (IQR) OR (95% CI) p-value
Male sex 56 (26%) 0.66 (0.37 - 1.17) 0.153 
Median (IQR) age (yrs) at FEVL 41 (33-47) 1.01 (0.99 -1.03) 0.415 
Facility        1 113 (45%) 1 
Facility    2 85 (34%) 1.54 (0.86 - 2.74) 0.142 
Facility    3 52 (21%) 1.03 (0.53 -1.99) 0.929 
Cohort    2007-2014 99 (40%) 1 
 2015-2017 151 (61%) 0.77 (0.46-1.29) 0.326 
WHO-stage at ART initiation:    1  24 (10%) 1 
WHO stage at ART initiation:    2 63 (25%) 0.23 (0.07-0.77) 0.016 
WHO stage at ART initiation:    3/4 160 (64%) 0.24 (0.08-0.73) 0.012 
WHO stage at ART initiation:    not recorded 3 (1%) 0.10 (0.01-1.38) 0.086 
Non-ART-naive at start  38 (15%) 1.19 (0.59-2.42) 0.615 
Median (IQR) CD4 at ART initiation (n=173) 171 (81-282) 1.00 (0.99-1.00) 0.735 
CD4 at FEVL (n=87) 188 (95-332) 1.00 (1.00-1.00) 0.927 
Log FEVL  4.3 (3.7-4.9) 0.74 (0.54-1.00) 0.052 
Time (mo) on ART at FEVL        ≤24 mo 108 (43%) 1 
  24 - 48  mo 69 (28%) 1.12 (0.61-2.08) 0.700 
 > 48  mo 73 (29%) 0.93 (0.51-1.69) 0.823 
Time (mo) on first-line ART 40 (22-62) 1.00 (0.99-1.01) 0.516 
Regimen at start containing TDF (vs ABC/AZT) 79 (32%) 1.48 (0.85-2.56) 0.166 
Regimen at start containing NVP (vs EFV) 119 (48%) 0.69 (0.42-1.15) 0.153 
Ever on second-line : yes  145 (58%) 1.19 (0.72-1.98) 0.495 
Number of visits/year  7.5 (4.7-10.4) 1.01 (0.95-1.07) 0.676 
Number of VL/year  0.9 (0.6-1.4) 1.09 (0.68-1.74) 0.728 
Time (mo) between FEVL and second VLa:    ≤ 3 mo 38 (16%) 1 
      3 - 6  mo 151 (63%) 0.81 (0.38-1.72) 0.577 
> 6  mo 51 (21%) 0.30 (0.12-0.72) 0.007 
Second-line regimen containing TDFb 86 (72%) 1.22 (0.53-2.78) 0.641 
Time (mo) between second VL and switchb: ≤ 1 mo  57 (48%) 1 
 1 - 3   mo 43 (36%) 0.45 (0.19-1.06) 0.069 
 > 3   mo 10 (8%) 0.49 (0.12-1.98) 0.316 
 switch before second VL 10 (8%) 0.22 (0.05-0.88) 0.033 
ABC = abacavir, ART= antiretroviral treatment, AZT = zidovudine, CI = Confidence Interval, mo = month/s, EFV = efavirenz , FEVL = first VL ≥ 1000 copies/ml >75 days after ART 
start, IQR = interquartile range, NVP = nevirapine, TDF = tenofovir, WHO = World Health Organization, yrs = years.  
a restricted to 240 patients with a second VL.   
b restricted to 120 patients switched to second-line ≤270 days after FEVL. 
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The study is based on routinely collected programmatic data and meets the following criteria for exemption 
from the MSF ERB review: 
1. Studies/articles are based on routinely-collected program data.
The study entitled ‘Nurse-led management of antiretroviral treatment failure: patient outcomes from 
Kinshasa, Democratic Republic of Congo’ is entirely is based on routinely collected data from the health 
centres of Kimia, Lisanga and Roi Beaudoin in Kinshasa, DRC. The data used for the analysis are data on patients 
on antiretrovirals (ART) attending these clinics, which are routinely entered into their medical records and 
transferred to the electronic Tier.net database, which is the national database for all ART patients.  
2. They are either descriptive/evaluative or targeted evaluations.
This is a descriptive evaluation of data of ongoing program data. The study looks at outcomes of patients who 
are routinely enrolled, treated and managed in decentralised facilities by nurses, particularly patients who 
have resistance to first line treatment. The study will also describe the framework of activities of the Kinshasa 
project to decentralize care, implement viral load monitoring, provide second-line treatment, and task-shifting 
of the activities to nurses.
The results will be used to inform policy around task shifting of second line switch and care in the DRC and 
beyond, with the potential to benefit patients and health care workers worldwide.  
3. Confidentiality is respected; no individual patient identifiers are revealed or used.
Investigators who will do the analysis will receive the secondary data anonymised and coded. These data will 
be imported into Stata and kept in a de-identified form. Participants names will thus not be used in this
study and only aggregate data will be presented. Facility names will not be made public but will be coded.
Confidentiality will be maintained by keeping data collection forms locked in a secure cabinet, while the
electronic data file will be kept in a password and firewall protected computer. Forms, lists, logbooks and
any other lists that link participant code to other identifying information will be stored in a separate, locked
file in an area with limited access. Data sets will be maintained securely for five years after completion of the 
study.
4. Harm is minimal but acknowledged where relevant.
This retrospective analysis does not cause any physical harm to participants, who did not receive differential 
treatment as compared to other patients in the DRC, resulting from this study. Nevertheless, use of medical 
data beyond the immediate clinical care exposes the patient to possible breaches of confidentiality, including 
the patients’ HIV status. Evaluation of nurse adherence to protocols entails a possible risk of retaliation for 
those nurses who do not adhere optimally. These risks ar minimised by anonymizing data and allowing only 
investigators access to data and databases.
5. Potential benefits to both the program and the community are described. Since the goal is
publication, the relevance to a wider audience is described.
There are no direct benefits resulting from study participation. There are potential benefits for patients 
attending the analysed facilities under investigation and beyond, and for care and treatment for ART patients 
in general. A better understanding of risk factors for adverse outcomes in second line patients and protocol 
implementation may lead to better care and patients’ outcomes in the included facilities, the DRC and beyond. 
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protocol implementation may lead to better care and patients’ outcomes in the included facilities, the DRC 
and beyond. As there is currently a gap in the literature on nurse-managed care for second-line patients, the 
results of this study are of key importance for policy and practise nationally and internationally.  
1. Collaborative involvement and, if applicable, authorship from a local authority or partner
(Ministry of Health, DHO, other NGO) is encouraged. If relevant and applicable, consultation with
a body representing the community is desirable.
In this case, the study is a retrospective analysis of program data and larger collaboration was not done a 
priori. However, engagement will be sought of the Ministry of Health in the DRC for critical reading of the 
manuscript and findings from the study will be shared widely with Ministry of Health counterparts in DRC as 
well as inform MSF program strategy in the decentralised facilities.  
2. If the decision for exemption from review is taken by the respective medical director, the
responsibility to ensure that ethical requirements are met lies with MSF. This, however, does not
exempt MSF from complying with any relevant regulatory requirements in the country from
where the data originate. In some countries, local ethical review may still be required.
The protocol will be submitted for full review by the Comite d’Ethique of the Ecole de Santé Public of the 
University of Kinshasa. It will also be submitted for full review by the Institutional Review Board of the 
University of Cape Town, South Africa.  
This research fulfilled the exemption criteria set by the Médecins Sans Frontières 
Ethics Review Board for a posteriori analyses of routinely collected clinical data and 
thus did not require MSF ERB review. It was conducted with permission from the 
Medical Director, Operational Centre Brussels, Belgium. 
Dr Petros Isaakidis - Operational Research Coordinator 
------------------------------------------------------------------------------------ 
Médecins Sans Frontières | Doctors Without Borders | 
Southern Africa Medical Unit (SAMU) 
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reviews; nor studies that make use of data, infrastructure or personnel in a foreign 
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are sent to at least two referees. If appropriate, a statistical reviewer is involved. 75% of papers 
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Preprint Servers 
Tropical Medicine & International Health will consider for review articles previously available as 
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artefacts supporting the results in the paper by archiving it in an appropriate public repository. 
Authors should include a data accessibility statement, including a link to the repository they have 
used, in order that this statement can be published alongside their paper. 
Word limits 
We are strict about concise writing. In principle, we enforce a word limit of 3,500 for the main 
body of the manuscript, but we will allow authors to exceed this where necessary for large-scale 
studies, studies with multiple outcomes being reported, randomised trials and reviews. 
Reviews 
We prefer systematic reviews written according to Cochrane Guidelines but will also consider 
critical reviews in areas where these are more appropriate. Reviews are published with free full 
access from the journal's homepage ( www.tmih.com). 
Editorials 
Editorials are short opinion papers. They have a length limit of 1,500 words including the 
references. Editorials are published with free full access from the journal's homepage 
(www.tmih.com). 
Supplements 
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References and quotations 
People quoted as originators of personal communications must have agreed to be cited. 
Short verbatim quotations must be in quotation marks and referenced. Long quotations must be 
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